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Characterization of The Roles of CARMA3 and BCL10 in Virus-Triggered RIG-
I/MAVS Signaling Pathway 
 
Zhicheng Zhou, M.S. 
Advisory Professor: Xin Lin, Ph.D. 
ABSTRACT 
After RNA virus infection, the innate immunity utilizes RIG-I family of receptors in the 
cytoplasm to initiate the production of type-I IFNs and proinflammatory cytokines by mitochondrial 
protein MAVS, which forms a prion-like structure to recruit TBK1and IKK complex to activate IRF3 
and NF-κB, respectively. Herein, we revealed the important roles of CARMA3 and BCL10 in RIG-
I/MAVS signaling pathway for the first time. CARMA3 or BCL10 deficient cells exhibited partially 
defective NF-κB activation but hyperactivation of TBK1-IRF3 signaling pathway upon ssRNA virus 
infection. It led to less production of IL6 but more production of type I IFNs and resulted in 
CARMA3-deficient mice more resistant to virus infection, including VSV and H1N1 influenza virus. 
Mechanistic studies showed that CARMA3 and BCL10 physically interacted with MAVS and 
directly regulated MAVS aggregation. Overexpression of CARMA3 and BCL10 inhibited MAVS 
aggregation. Consistently, MAVS aggregation more easily occurred in CARMA3 deficient cells after 
VSV infection. VSV induced the cleavage of CARMA3 and led to more MAVS aggregation. These 
novel findings not only identified the important role of CARMA3 and BCL10 during influenza virus 
infection, which may provide the new target for future therapeutic interference but also revealed 
molecular mechanism by which CARMA3 and BCL10 orchestrated the NF-κB and IRF3 activation 
to balance the production of type I IFNs and proinflammatory cytokines. 
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CHAPTER 1: INTRODUCTION 
 
 
The essential event of immunology system is to recognize the microbial pathology and to 
initiate the appropriate immune responses to fight against invasion pathology. In this process, 
pattern recognition receptors (PRRs) recognize small molecular motifs conserved within a 
class of microbes, also known as pathogen-associated molecular patterns(PAMPs) and 
activate a serious of signaling pathways to initiate innate immunity(Janeway 2013). The 
well-characterized mammal PRRs include membrane-associated Toll-like receptors(TLRs), 
c-type lectin receptors(CLRs), cytosolic receptors such as NOD-like receptors(NLRs), RIG-I 
like receptors(RIRs) and AIM2-like receptors (ALRs)(Kawai and Akira 2011). Since our 
research mainly focused on two RNA virus, influenza A virus and vesicular stomatitis 
Indiana virus (VSV), the following chapter mainly describes the receptors and their 
downstream signaling pathways that are involved in RNA virus detection and clearance. 
 
1.1 Toll-like receptors 
 
TLRs are the first PRRs to be characterized. They comprise a large family of membrane-
bound receptors, which are named from their similarity to the toll protein of drosophila 
identified in 1985 (Hansson and Edfeldt 2005). The vertebrate TLR family consists of 13 
members, including TLR1, TLR2, TLR3, TLR4, TLR6, TLR7, TLR8, TLR9, TLR10, 
TLR11, TLR12 and TLR13, which are characterized by extracellular domain containing 
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leucine-rich repeats (LRRs), a transmembrane region and a cytoplasmic Toll/IL-1 receptor 
(TIR) domain(Lester and Li 2014). Each receptor senses the PAMPs derived from diverse 
microbes, including bacterial cell wall components such as  lipoproteins(for TLR1, TLR2, 
and TLR6), lipopolysaccharide(LPS)(for TLR4), as well as bacterial flagellin(for TLR5), 
bacterial DNA(for TLR9),virus-derived double stranded(dsRNA)( for TLR3) and single-
stranded(ssRNA)(forTLR7 and TLR8)(Table 1)(Akira, Uematsu et al. 2006).  
Upon ligand recognition, TLRs recruit a serious of adaptor proteins to activate 
downstream signaling pathways. Based on different adapters, these signaling pathways can 
be divided into two types, myeloid differentiation primary response gene (88) (MyD88)- and 
the TIR-domain containing adaptor inducing IFN-β (TRIF)-dependent pathways. TLR3 and 
TLR4 recruit TRIF, while other TLRs with the exception of TLR3 utilize MyD88. Through 
these adapters, TLRs trigger the activation of nuclear factor kappa-light-chain-enhancer of 
activated B cells(NF-κB)/ the activator protein 1 (AP-1) and distinct IFN regulatory factor -3 
and -7(IRF3/7) pathways to orchestrate innate and adaptive immune responses against the 
invasion of diverse pathogens(Kawai and Akira 2011).  
TLRs play an important role in antivirus immune response. Viruses depend on the host 
cells to complete their replication cycle. During the virus life cycle, the virus-derived PAMPs 
are recognized by TLRs. The role of TLRs is to trigger the production of IFN (IFN) and/or 
proinflammatory cytokines.  It has been shown that TLR3, TLR7/TLR8/TLR9, TLR4 and 
TLR2 have an important impact on antivirus innate immunity(Fig.1)(Lester and Li 2014).   
TLR3 is located in endosome and is the first well-studied nucleotide-sensing TLR 
(Alexopoulou, Holt et al. 2001). TLR3 recognizes virus-derived dsRNA, a molecular 
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signature of many RNA viruses. Polyriboinosinic:polyribocytidylic acid (poly(I:C)),a 
synthetic dsRNA analog, also triggers the activation of TLR3-dependent signaling pathways. 
The in vitro binding assay revealed that TLR3 ectodomain was capable of interacting with 
the dsRNA with the length of 40–50 bps long, while the TLR3 signaling was activated by 
ligand with the length of 90bps or longer(Leonard, Ghirlando et al. 2008). As a PAMP, 
dsRNA itself constitutes virus genome or is generated as a replicative intermediate during 
virus life cycle. Therefore, TLR3 recognizes multiple types of viruses, including dsRNA 
virus, ssRNA virus and DNA virus. Upon viral dsRNA recognition, TLR3 undergoes 
tyrosine phosphorylation on Tyr858 and Tyr759 in its cytoplasmic domain (Lee, Xu et al. 
2012, Yamashita, Chattopadhyay et al. 2012). Upon activation, the receptors recruit the 
TRIF- TNF receptor associated factor 6(TRAF6) - receptor-interacting protein 1(RIP1) 
complex, which leads to the activation of transforming growth factor beta activated kinase 
1(TAK1) and subsequently the classical IκB kinase (IKK) complex (Sato, Sugiyama et al. 
2003, Jiang, Mak et al. 2004, Meylan, Burns et al. 2004). Then, the activated IKK complex 
phosphorylates nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, 
alpha (IκBα) on its serine 32 and 34 and causes it to be degraded by the proteasome, which 
will release NF-κB dimmers.  The free NF-κB dimmers enter the nucleus and turn on the 
transcription of the specific genes with the κB site in the promoter (Kawai and Akira 2011).  
On the other hand, TRIF associates with TRAF3 to activate the noncanonical IKK kinases, 
TBK1 and/or IKKε. The activated TBK1 and IKKε phosphorylate and activate IRF3 and 
IRF7. The phosphorylated IRF3 and IRF7 undergo the dimerization and then go into the 
nucleus to induce the production of type I and/or type III IFNs. These proinflmmatory 
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cytokines and IFNs serve as the first defense line against virus infection.  Therefore, during 
virus infection, any dysregulation of TLR3 singling results in severe outcomes. For example, 
mice lacking TLR3 are hypersensitive to the infection of  mouse cytomegalovirus (MCMV), 
herpes simplex virus (HSV) 2, poliovirus, encephalomyocarditis virus (EMCV), coxsackie 
virus B3 or B4, rotavirus etc., as it is evidenced by the significantly increased viral shedding 
and decreased production of antiviral and proinflmmatory cytokines(Hoebe, Du et al. 2003, 
Tabeta, Georgel et al. 2004, Herman, Ciancanelli et al. 2012). This in vivo evidence confirms 
the importance of TLR3 in antivirus immune response. 
Similar to TLR3, TLR7 and TLR8 are also located in endosome. They recognize GU-rich 
and AU-rich ssRNA sequence of RNA viruses, including  the human immunodeficiency 
virus (HIV-1), VSV, sendai virus, coxsackie B virus, coronaviruses, flaviviruses, such as 
HCV, dengue virus and WNV(Diebold, Kaisho et al. 2004, Heil, Hemmi et al. 2004, Lund, 
Alexopoulou et al. 2004). In recognition of viral-derived ssRNA in endosome, TLR7 or 
TLR8 utilizes MyD88-dependent pathways to activate NF-κB and IFN regulatory factor 
(IRF7). More specifically, the TLR7 or TLR 8 recruits interleukin-1 receptor-associated 
kinase (IRAK4), interleukin-1 receptor-associated kinase (IRAK1) and many E3 ubiquitin 
ligases, such as TRAF6 and TRAF3, through MyD88. It leads to the activation of IKKa and 
TAK1. TAK1 directly phosphorylates IKKβ in the IKK complex and subsequently activates 
NF-κB signaling pathway. In parallel, IKKα and IRAK1 phosphorylate and activate IRF7, 
resulting in the production of IFN alpha (Hemmi, Kaisho et al. 2002, Kawai, Sato et al. 2004, 
Honda, Yanai et al. 2005).  Also, the tissue distribution of TLR7 and TLR8 suggests their 
important role in innate immunity.  Different from TLR3 with wide tissue distribution , 
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TLR7 is predominatly expressed in plasmacytoid dendritic cells (pDCs), B cells and 
monocytes/macrophages, while TLR8 is only found in monocytes/macrophages and myeloid 
dendritic cells(Lester and Li 2014).  
TLR9 is another endocytic PRR, which recognizes unmethlated CpG motifs, a PAMP of 
many bacterial  and viral DNA.  The unmethlate CpG is always found in microbial genomes 
but rare in verterbrate genome, by which TLR9 can discriminate host DNA from microbe-
derived DNA(Latz, Schoenemeyer et al. 2004). Besides, the intracellular localiztion of TLR9 
decreases the risk responding to self DNA and developing autoimmune disease.  TLR9 is 
expressed in many immune cells including macrophage, B cells, myeloid dendritic cells, 
classical dendritic cells(cDCs) and pDCs. Similar to TLR7 and TLR8, TLR9 utilizes 
MyD88-dependent pathways to activate IRF7 and NF-κB. Mice with TLR9 deficiency are 
hypersusceptible to many double-stranded  DNA virus infection, including mouse 
cytomegalovirus (MCMV), HSV 1 and HSV 2, and poxviruses(Lund, Sato et al. 2003, Krug, 
Luker et al. 2004, Tabeta, Georgel et al. 2004).  
Unlike endocytotic TLRs, TLR2 and TLR4 are located in cell membrane, which 
recognize viral envelop proteins or viral proteins that are released to extracellular milieu.  For 
example,  TLR2 recognizes the core and NS3 proteins of HCV, the glycoproteins B and H of 
human cytomegalovirus, the glycoproteins, such as gH/gL and gB of HSV, the UTPase of 
EBV and hemagglutinin(HA) protein of measles virus and nsp4 of rotavirus(Bieback, Lien et 
al. 2002, Compton, Kurt-Jones et al. 2003, Boehme, Guerrero et al. 2006, Ariza, Glaser et al. 
2009, Leoni, Gianni et al. 2012). TLR4 recognizes the VSV-G protein of VSV, the GP 
protein of Ebola virus, the envelop protein of MMTV and so on (Georgel, Jiang et al. 2007, 
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Ariza, Glaser et al. 2009, Okumura, Pitha et al. 2010). After engagement of ligands, TLR2 
and TLR4 activate downstream signal pathways in different manners. Specifically, TLR2 
dimmerizes with other TLRs such as TLR1 or TLR6 on the cell membrane. Then, TLR2 
initiates MyD88-dependent pathways to activate NF-κB. The role of TLR2 in IFN production 
seems controversial, which may depend on the cells type and virus types. Different from 
TLR2, TLR4 does not form a heterodimer with other TLRs. TLR4 signal on the cell 
membrane is transduced via MyD88- and TRIF- dependent pathways.  In TLR4 signaling, 
the activation of early-phase NF-κB is linked to MyD88-dependent pathways, while the late 
phase NF-κB and IRF3/7 are activated by TRIF-dependent pathways(Lester and Li 2014).   
These TLRs sense diverse virus-derived PAMPs and constitute a powerful antiviral 
innate immune system to quickly react to invading viruses(Lester and Li 2014). 
 
1.2 RIG-I and MAVS signaling pathway 
 
The innate immunity utilizes not only TLRs but also RIG-I- like family receptors (RLRs) 
in the cytoplasmic compartments to detect viral infection. Upon activation, RIG-I initiates 
distinct signaling pathways to produce type I IFN and other proinflmmatory cytokines (e.g., 
TNFα and IL-6), which quickly limit virus infection and activate the adaptive immune 
system (Akira, Uematsu et al. 2006, Kawai and Akira 2006). 
Previous studies have identified several RLR family members, including RIG-I, 
melanoma differentiation associated gene 5(MDA5), and laboratory of genetics and 
physiology 2(LGP2). All of the three RLRs are DExD/H box RNA helicases and share very 
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similar domains, including the central DExD/H box RNA helicase domain with ATPase 
activity and the C‑terminal domain (CTD). Different from LGP2, RIG-I and MDA5 contain 
the N‑terminal domain (NTD) consisting of tandem CASPASE activation and recruitment 
domains (CARDs). Without CARD domains, LGP2 serves as a regulatory but not an 
essential component in RIG-I/MDA5/mitochondrial antiviral-signaling protein (MAVS) 
signaling pathway (Satoh, Kato et al. 2010). 
These functional domains contribute to the overall function of a protein. Among RLRs 
family proteins, only the structures of “active” and “silence” RIG-I have been well studied, 
therefore, we will take RIG-I as an example to interpret the function of domains in RLRs 
family proteins.  In resting cells, the N-terminal CARD domains are bound to the central 
helicase domain of the protein and thus, are not available for their function.  After RNA virus 
infection, the “free” CTD senses viral RNA and interacts with blunt-ended 5’ppp-
dsRNA.Then, the CTD competes with the CARD domains to interact with central helicase 
domain and release CARD domains. After that, the “free” CARD domains become 
potentially available for downstream adaptors, for example, MAVS. RIG-I interacts with 
MAVS through the CARD domains, which activates MAVS to form  prion -like structure. 
Then, the aggregated MAVS works as a platform in the mitochondrial to recruit the IKK and 
TBK1 complex to activate NF-κB and IRF3 signaling pathways, respectively (Hou, Sun et al. 
2011)(Fig. 2). Followed by ATP hydrolysis and phosphate release, the helicase domain no 
longer interacts with the CTD but binds to the CARD domain again. It results in the 
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dissociation of RIG-I from MAVS and stops the activation of signaling pathways (Zeng, Sun 
et al. 2010, Kolakofsky, Kowalinski et al. 2012). 
Although three RLRs share very similar protein structure, they do have some functional 
difference. For example, RIG-I and MDA5 can recognize different RNA viruses. RIG-I is 
essential for innate immunity to many ssRNA viruses, including influenza A and B virus, 
NDV, Sendai virus (SeV), respiratory syncytial virus, measles virus, VSV, rabies virus, HCV 
and Japanese encephalitis virus. After transcription of AT-rich DNA genome of DNA virus, 
RIG-I can recognize some DNA viruses including adenovirus, HSV1, and EBV (Sumpter, 
Loo et al. 2005, Hornung, Ellegast et al. 2006, Kato, Takeuchi et al. 2006, Samanta, Iwakiri 
et al. 2006, Plumet, Herschke et al. 2007, Saito, Hirai et al. 2007, Loo, Fornek et al. 2008, 
Ablasser, Bauernfeind et al. 2009, Chiu, Macmillan et al. 2009). Different from RIG-I, 
MDA5 protects host from the infection of EMCV, Theiler’s virus, mengovirus, murine 
norovirus, and murine hepatitis virus(Kato, Takeuchi et al. 2006, McCartney, Thackray et al. 
2008, Roth-Cross, Bender et al. 2008). Recognition of different viruses suggests that RIG-I 
and MDA can detect distinct features of RNA viruses. 5'-triphosphate RNA as well as short 
(<2 kbp) dsRNAs is the ligand for RIG-I, while MDA5 can be activated by transfection of a 
long (>2 kbp), synthetic dsRNA analog of artificial sequence, namely 
polyinosinic:polycytidylic [poly(I:C)](Hornung, Ellegast et al. 2006). Additionally, LGP2 is 
different from other family members. Without CARD domain, LGP2 cannot interact with 
adaptor protein MAVS and thereby, play a negative role in regulating RIG-I and MDA5-
mediated antiviral response (Satoh, Kato et al. 2010). 
  
9 
 
MAVS mediates antiviral response as an adapter protein for RLRs. MAVS was first 
identified by the four independent labs almost at the same time in 2005. Therefore, MAVS is 
also known as virus-induced signaling adapter (VISA), IFN-β promoter stimulator 1(IPS-1) 
and CARD adapter inducing IFN beta (Cardif) (Kawai, Takahashi et al. 2005, Meylan, 
Curran et al. 2005, Seth, Sun et al. 2005, Xu, Wang et al. 2005). Different from mice with 
loss of RIG-I, MAVS-deficient mice were viable and fertile. However, the knock-out mice 
fail to produce type I- IFN in response to poly (I:C) stimulation and increase mortality during 
virus infection. It suggests the important role of MAVS in innate immunity against viral 
infection (Sun, Sun et al. 2006). MAVS contains an N-terminal CARD followed by a 
proline-rich region and a transmembrane domain (TMD). These domains together contribute 
to the overall function of protein. The N-terminal CARD is important for MAVS interaction 
with upstream RLRs. The prolin-rich region in MAVS is required for the recruitment of 
many E3 ligases including TRAF2, TRAF5 and TRAF6. The TMD domain is important for 
MAVS mitochondrial localization. Being activated, MAVS forms a prion-like structure in 
the mitochondrial outer membrane and works as a platform to assembly a MAVS 
signalosome including TRAF2, TRAF3, TRAF6, TRAF family member-associated NF-κB 
activator (TANK), TNFR1-associated death domain protein (TRADD). The formation of a 
MAVS signaling complex leads to the activation of NF-κB and IRF3 to produce pro-
inflammation cytokines and type I IFNs. These secreted proteins become the first defense 
line against virus infection(Fig. 2)(Jacobs and Coyne 2013). 
 
1.3 IFN and antivirus response 
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After virus infection, host cells quickly releases IFNs, which provides the first defense 
line against virus invasion (Colonna, Krug et al. 2002). The IFNs were firstly discovered at 
the early 1950. It was found that virus-infected cells were resistant to the second virus 
infection under some conditions. However, people did not identify the substrate or agent 
responsible for this phenomenon at that time (Henle 1950). In 1957, Issacs and Lindenmann 
coined the term “IFN” to describe the substrate secreted by the cells to interfere the virus 
infection (Isaacs and Lindenmann 1957, Isaacs, Lindenmann et al. 1957). Twenty years later, 
the IFNs were firstly purified from the medium of stimulated human white blood cells 
(Cantell, Hirvonen et al. 1981, Cantell, Hirvonen et al. 1981). After the refinement of 
purification schemes, it was found that IFN was not one but a family of different 
proteins(Cantell, Hirvonen et al. 1981).  Until now, more than 20 distinct IFNs have been 
identified in animal, including humans(Schneider, Chevillotte et al. 2014). 
IFNs belong to a large family of cytokines. After virus infection, IFNs produced by cells 
are released into extracellular milieu, where they can be recognized by different IFN 
receptors(Schneider, Chevillotte et al. 2014). Based on different receptors, the IFNs are 
divided into three different classes, type I IFN, type II IFN and type III IFN. Type I IFN is 
the largest group in IFN family, including IFNα, IFNβ, IFNε, IFNκ and IFNω in 
humans(Schneider, Chevillotte et al. 2014). All type I IFN proteins are recognized by the 
type I IFN heterodimeric receptors, which consist of IFNα receptors 1(IFNAR1) and IFNα 
receptors 2 (IFNAR2). Type I IFN proteins can be produced by nearly all types of cells. 
Consistently, IFN receptors are ubiquitously expressed. Wide tissue distribution of IFNs with 
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their receptors suggests their important role in antiviral innate immunity(Schneider, 
Chevillotte et al. 2014). Different from type I IFNs, there are only one type II IFN, IFNγ. In 
the recognition of IFNγ, the type II IFN receptor forms a complex with interaction between 
two IFNγ receptor 1(IFNGR1) subunits and two IFNγ receptor 2(IFNGR2), which results in 
the activation of the receptors(Walter, Windsor et al. 1995). Although the type II IFN 
receptor is expressed on the cell surface of all cell types, the IFNγ is only produced by the 
cells of immune system and plays an important role in both innate and adaptive 
immunity(McLaren and Ramji 2009, Zaidi and Merlino 2011). In 2003, the type III IFN class 
was identified by two different groups (Kotenko, Gallagher et al. 2003, Sheppard, 
Kindsvogel et al. 2003). Until now, four different members have been identified. They are 
IFNL1, IFNL2, IFNL3 and IFNL4 (also known as IFN-λ1, IFN-λ2, IFN-λ3 and IFN-λ4) (Fox, 
Sheppard et al. 2009, Prokunina-Olsson, Muchmore et al. 2013). The structure of these 
proteins is similar to the proteins of the IL-10 cytokine family. Therefore, the type III IFNs 
bind to IL-10 receptor 2 with low-affinity. Additionally, the types III IFNs interact with type 
III IFN receptor with high affinity and activate downstream signaling pathways(Fox, 
Sheppard et al. 2009). Together, IFNs and their receptors constitute an immune system in 
response to virus infection (Fig. 3). 
Although distinct IFNs can be recognized by different receptors, they share janus kinases 
(JAKs)- signal transducers and activators of transcription(STATs) signaling pathway to 
increase the transcription of IFN-stimulated genes (ISGs)(Stark and Darnell 2012). In resting 
cells, the JAKs interact with the cytoplasmic domain of each IFN receptor subunits in an 
inactive form. Upon ligand stimulation, receptor chains undergo conformational change to 
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bring the kinase domains of JAKs into close proximity, where JAK are autophosphorylated 
and subsequently activated. Then, the “active” JAKs in turn phosphorylate the cytoplasmic 
part of IFN receptors on some conserved tyrosine residues, which works as the docking sites 
for STAT proteins. The Src homology domain2 (SH2) on STAT is responsible for STAT-
receptor interaction. The receptor-recruitment of STAT proteins is essential for 
phosphorylation and activation of STAT proteins. After phosphorylation, STAT proteins 
undergo conformational change and form a homo-(type II IFN) or heterodimer (type I and 
type III IFN). Then, STAT dimmers are released from IFN receptors and enter the nucleus, 
where they serve as transcriptional factor to drive expression of ISGs (Schindler, Shuai et al. 
1992, Shuai, Schindler et al. 1992, Greenlund, Morales et al. 1995, Heim, Kerr et al. 1995, 
Sekimoto, Imamoto et al. 1997, Melen, Kinnunen et al. 2001, Fagerlund, Melen et al. 2002, 
McBride, Banninger et al. 2002, van Boxel-Dezaire, Rani et al. 2006) (Fig. 3). 
ISGs are involved in a wide of cellular activities. They limit virus infection by directly 
targeting proteins or functions involved in the virus life cycles. In absence of virus, ISGs are 
kept in a low level. After virus infection, the induction of ISGs takes places through PRRs-
triggered signaling pathways to reinforce the IFN response and prime antiviral immune 
response(Schneider, Chevillotte et al. 2014).   
Virus relies on host cells to complete their life cycle, which includes cellular entry of 
virus, translation and replication of viral genomes and viral shedding(Schneider, Chevillotte 
et al. 2014). ISGs target these stages of viral life cycle through different mechanisms. For 
example, the murine myxovirus resistance 1 and 2(Mx1 and Mx2) are two important ISGs 
targeting the cellular entry of virus. Both of them are small guanosine 
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triphosphatases(GTPase)(Schneider, Chevillotte et al. 2014). Mx1 traps uncoating of 
ribonuclocapsids and thereby, interferes endocytic traffic of incoming virus particles (Gao, 
von der Malsburg et al. 2010). In this way, MX1 prevents viral components from reaching 
their cellular destination and inhibits the translation and replication of viral genome. 
Similarly, MX2 inhibits the replication cycle of HIV-1 by preventing viral reverse-
transcribed genome from reaching its nuclear destination (Kane, Yadav et al. 2013).  Another 
set of ISGs inhibits viral replication and translation, such as the IFN-induced protein with 
tetratricopeptide repeats (IFIT) family, the OAS-RNaseL pathway, PKR and zinc-finger 
antiviral protein (ZAP) (Goff 2004, Kok and Jin 2013, Munir and Berg 2013). Furthermore, 
many ISGs execute their inhibitory functions at the last stage of virus life cycle. Viperin and 
tetberin are two good examples. Upon influenza or HIV infection, the amount of viperin was 
induced, which affected plasma membrane fluidity through disrupting lipid rafts.  The lipid 
rafts with appropriate membrane fluidity is perquisite for influenza or HIV shedding.  By 
disrupting lipid rafts, viperin blocks virus shedding (Wang, Hinson et al. 2007, Nasr, 
Maddocks et al. 2012). Different from viperin, tetberin directly traps virus particles on the 
plasma membrane through utilizing two membrane anchors (Perez-Caballero, Zang et al. 
2009).   
Another important role of ISGs is to desensitize cellular IFN response. IFN response not 
only renders cells resistance to virus infection but also triggers inflammation. Under some 
conditions, the sustained IFN response leads to apoptosis. Therefore, in some cases, the 
hyperactivation of IFN signaling pathway can cause severe outcomes.  To return cellular 
homeostasis, many ISGs reduce the activation of the JAK-STAT signaling pathway to 
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negatively regulate IFN signal(Schneider, Chevillotte et al. 2014). Among them, suppressor 
of cytokine signaling proteins (SOCS) and ubiquitin-specific peptidase 18(USP18) undergo 
intensive investigation. SOCS directly interacts with IFN receptors or the JAK proteins and 
serves as pseudosubstrates of the kinase. Therefore, it inhibits the activation of JAK-STAT 
signaling pathway(Hong and Carmichael 2013). The induction of USP18 results in a more 
sustained inhibition of IFN signaling. USP18 interacts with the cytoplasmic part of IFNα 
receptor2 (IFNAR2), which leads to the conformational changes of the extracellular domain 
of IFNAR2. It keeps the IFNAR from binding with IFNα and shut down the JAK-STAT 
signaling cascade.  In contrast, USP18 also interacts with IFNβ receptor but cannot inhibit 
the signaling cascade, which may due to the IFNβ interact with its receptor with high affinity. 
It seems that USP18 specifically inhibits IFNα signaling, since it does not interact with type 
II and type III IFN receptors(Schneider, Chevillotte et al. 2014). 
 In sum, ISGs play an important role in regulating the antiviral immune responses and 
keeping cellular homeostasis, which is important for the host cells to survival and control the 
infection of pathogen. 
 
1.4 NF-κB signaling pathway and CARMA family members 
 
The prototype of NF-κB is referred as p65 and p50 heterodimer. They belong to a family 
of transcription factors that regulate the transcription of various genes involved in diverse 
cellular activities including inflammation, immune response, cell growth, apoptosis, 
differentiation and etc. The NF-κB family has five members, which are NF-κB1 (p105/p50), 
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NF-κB2 (p100/p52), RELA (p65), RELB and c-Rel. All NF-κB proteins contain Rel 
homology domain (RHD) in their N-terminus, which plays an important role in NF-κB 
protein’s dimerization and DNA binding. The difference among members lies in their 
transcription domain. According to the presence of transcription domain, the NF-κB family 
proteins are classified into two groups. The first group consists of RELA, RELB and c-Rel. 
They contain a transactivation domain in their C-terminal and are synthesized as mature 
proteins. The second group includes NF-κB1 and NF-κB2. They do not have a 
transactivation domain but instead C-terminal ankyrin repeats. They are large precursors and 
undergo processing through the ubiquitin/proteasome pathway to generate the mature 
proteins, p50 and p52 respectively. This processing is to selectively degrade NF-κB1 and 
NF-κB2’s C-terminal regions. (Hayden and Ghosh 2004, Natoli 2010).   
Two distinct NF-κB signaling pathways have been characterized, namely the canonical 
and non-canonical pathway. In the canonical NF-κB signaling pathway, in quiescence cells, 
NF-κB dimmers are associated with IκB proteins that block the NF-κB nuclear localization 
domains and thereby, preventing translocation of NF-κB into the nucleus.  The canonical NF-
κB signaling pathway is activated by a wide variety of receptors, including receptors for 
proinflammatory cytokines, such as tumor necrosis factor α (TNFα) and interleukin-1β (IL-
1β), TLRs, TCRs, growth factor receptors, such as epithelial growth factor receptor family 
members, and G protein-coupled receptors (GPCR). Upon receipt of appropriate signals, 
many signaling cascades are activated, leading to activation of the IκB kinase (IKK) 
complex. Activation of the IKK complex results in IκBα phosphorylation at Ser32 and Ser36, 
ubiquitination, and degradation, which frees the NF-κB dimers. Then, the free NF-κB 
  
16 
 
dimmer translocates from the cytoplasm into the nucleus and facilitates transcription of its 
target genes (Hayden and Ghosh 2004, Perkins 2007). 
Different from the canonical NF-κB signaling pathways, the non-canonical NF-κB 
signaling pathway is thought to mainly mediate the adaptive immune functions. The 
activation of non-canonical NF-κB pathway relies on the stabilization of NF-κB inducing 
kinase (NIK). In resting cells, NIK is constantly degraded in a TRAF3-dependent manner. In 
brief, inhibitor of apoptosis (cIAP) proteins target NIK for ubiquitination and continuous 
proteasomal degradation through tumour necrosis factor receptor associated factor 2 (TRAF2) 
and TRAF3.  TRAF3 serve as an adaptor that directly brings NIK to the TRAF2–cIAP 
complex through TRAF3 interaction with TRAF2(Gyrd-Hansen and Meier 2010). Upon 
receiving appropriate signals, TRAF3 undergoes K-48 linked ubiquitination and consequent 
degradation, which frees NIK from its E3 complexes. Then, the NIK is stabilized and 
activates its downstream kinase IKKα. The activated IKKα phosphorylates S866 and S870 
on the NIK-responsive domain of p100.  These two phosphorylation residues, S866 and S870 
sites, serve as docking sites of the SCFβTrCP ubiquitin ligase complexes. The upstream lysine 
(K) residue, K856, on p100 works as the ubiquitin acceptor site. The phosphorylation and 
ubiquitination of p100 facilitate its proteasomal processing to p52 through the deletion of c-
terminal of p100(Oeckinghaus and Ghosh 2009). Then, p52 and RelB heterodimers enter the 
nucleus and regulate the expression of genes, including cxcl12, cxcl13 and etc. These genes 
play an important in B cell homeostasis and lymph node(Oeckinghaus and Ghosh 2009).  
Recent studies have revealed the unexpected role of non-canonical NF-κB signaling 
pathway in innate immunity (Jin, Hu et al. 2014). Mice and cells with genetic deficiencies in 
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non-canonical NF-κB components produced more type I IFN upon dsRNA virus infection. 
As a result, the mice and cells were more resistant to viral infection.  Besides, the authors 
found that the virus-induced activation of non-canonical NF-κB suppressed the recruitment 
of a histone demethylase, JMJD2A and transcriptional factor RelA to the ifnβ promoter, 
which play important role in the infβ transcription (Jin, Hu et al. 2014). In this way, non-
canonical NF-κB signaling pathway works synergistically with canonical NF-κB signaling 
pathway to regulate type I IFN induction and thus, is involved in host anti-virus response. 
While there has been tremendous progress in revealing the NF-κB signaling pathways in 
the context of different situations, it still remains to be seen what is the mechanistic details 
regarding stimulation-specific activation of IKK complex.  The scaffold complexes are 
thought to serve as a platform in determining NF-κB activation in different context. Among 
different scaffold proteins, members from Caspase Recruitment domain(CARD)- and 
membrane-associated guanylate kinase-like domain-containing protein (CARMA) , play an  
important role in regulating IKK activities(Blonska and Lin 2011). 
CAMAR family has three members, CARMA1, CARMA2 and CARMA3, which are 
encoded by different genes. They are conservative among different species and share very 
similar structure homology. There is an N-terminal CARD domain, followed with a coiled-
coil domain(C-C), a PDZ domain, an SH3 domain, and a the C-terminal guanylate kinase-
like (GUK) domain in all family members. Each domain has its own unique function and 
together contributes to overall protein functions. Since the functions of CARMA1 are well 
studied, we will take CARMA1 as an example to introduce the function of domains located 
in CARMA family proteins. Original study suggested that CARMA1 was required for T cell 
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receptor (TCR)-induced NF-κB activation (Gaide, Favier et al. 2002, Wang, You et al. 2002, 
Blonska and Lin 2011). In resting status, CARMA1 is kept in the inhibitory conformation. 
Upon stimulation, CARMA1 is recruited into the immunological synapse through its 
MAGUK domain and its adaptor protein known as adhesion and degranulation-promoting 
adapter protein. In immunological synapse, PKCβ (in the B cells) or PKCθ (in the T cells) 
can phosphorylate CARMA1 at the linker region between the C–C and PDZ domain, which 
leads to the release of CARMA1 autoinhibition(Matsumoto, Wang et al. 2005, Sommer, Guo 
et al. 2005). Then, the “activated” CARMA1 undergoes auto-oligomerization  and recruits its 
partner B-cell lymphoma (Bcl10) to form CARMA1/Bcl10 complex (Jiang and Lin 2012). In 
the complex, CARMA1 serves as nucleator of Bcl10 polymerization. Then, CARMA1/Bcl10 
complex further interacts with paraCASPASE mucosa-associated lymphoid tissue lymphoma 
translocation protein 1(MALT1) to form CBM signalosome and regulates NF-κB activities 
(Qiao, Yang et al. 2013).   
Although CARMA proteins shared very similar domains, they have different tissue 
distribution.  CARMA1 is only expressed in the hematopoietic tissues, whereas CARMA3 is 
expressed in the non-hematopoietic tissues and CARMA2 is expressed in the placenta, skin 
and mucosal tissues (Bertin, Wang et al. 2001, Gaide, Martinon et al. 2001, McAllister-
Lucas, Inohara et al. 2001, Wang, Guo et al. 2001). The distinct tissue distribution of 
CARMA proteins indicates that they may regulate NF-κB signaling pathway by forming the 
complex with BCL10 and MALT1 in a similar manner but in different tissues.  Consistent 
with this concept, BCL10 and MALT1 are expressed in all tissues(Jiang and Lin 2012).  
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Although the role of CARMA1 in NF-κB signaling pathway had been intensively studied, 
the function of other CARMA proteins has not been well characterized. Original studies 
showed that CARMA3 interacted with Bcl10 and activated NF-κB, when they are 
overexpressed in the mammalian cells (Wang, Guo et al. 2001). The following studies mainly 
focus on the role of CARMA3 in some GPCRs signaling pathways. GPCRs are also known 
as seven-transmembrane domain receptors (7TM receptors), serpentine receptors, and G 
protein-linked receptors (GPLR), which comprises the largest integral membrane protein 
family encoded in the human genome with nearly 1000 members. Many of them can activate 
NF-κB through PKCs(Jiang and Lin 2012). Since CARMA1works downstream of PKC in 
antigen receptor-induced NF-κB activation, it is reasonable to hypothesize that CARMA3 
plays a similar role downstream of PKC and is involved in some GPCR-induced NF-κB 
activation. Indeed, the researchers showed there were the defects of IKK and NF-κB 
activation in CARMA3 deficient mouse embryonic fibroblasts (MEFs) after exposure to 
lysophosphatidic acid and endothelin-1, which are ligands for two distinct GPCRs. 
Mechanistically, CARMA3 interacts with Nemo and regulate Nemo-associated 
polyubiquitination, by which CARMA3 deficiency leads to the impaired kinase activity of 
IKK complex(Grabiner, Blonska et al. 2007). Consistently, it has been found that Bcl10 and 
MATL1 also play an essential role in some GPCR-induced NF-κB activation in different 
cellular context (McAllister-Lucas, Ruland et al. 2007, Wang, You et al. 2007, Rehman and 
Wang 2009, McAllister-Lucas, Jin et al. 2010). In summary, these studies suggest that CBM 
complex is required for GPCR-induced NF-κB activation. 
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Recently, a study has revealed the important role of CARMA3 in the epidermal growth 
factor receptor (EGFR)-induced activation of NF-κB (Jiang, Grabiner et al. 2011). EGFR is a 
transmembrane tyrosine kinase receptor and belongs to the HER family of receptor. EGFR 
plays an essential role in regulating cell proliferation and differentiation, by which EGFR 
contributes to a number of malignancies. EGFR activates many downstream signaling 
cascades, including signaling pathway leading to activation of NF-κB signaling pathway, 
through its receptor tyrosine kinases (RTK). Both CARMA3 and BCL10 deficiency impairs 
EGF-induced activation of the IKK complex, resulting in a defect of IκBα phosphorylation 
and NF-κB activation.  Furthermore, CARM3 and BCL10 contribute to EGFR-associated 
malignancy both in vivo and in vitro (Jiang, Grabiner et al. 2011). Several studies support the 
clinical significance of CARMA3 in different types of cancer.  For example, in non-small-
cell lung cancer (NSCLC), the overexpression of CARMA3 correlates with cancer 
progression, EGFR mutation and overexpression (Li, Qu et al. 2012).  Besides, in colon 
cancer, CARMA3 is overexpressed, which facilitates the disease progression by regulating 
NF-κB mediated transcription of cyclin D1 (Miao, Zhao et al. 2012).  
Although significant progresses have been made to understand the function of CARMA3 
in NF-κB signaling pathway, the precise mechanism remains largely unknown.  Future 
investigations are needed to answer these questions: 1) how is CARMA3 activated in 
different cellular context? 2) How is the CARMA3 linked for the receptors? 3) Which PKCs 
is involved in regulating CARMA3 complex? 4) Does CARMA3 contribute to other 
signaling pathways or diseases?   These studies will provide us the insight into the molecular 
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mechanism of CARMA3 in NF-κB signaling pathway, by which the researchers can develop 
interference therapeutic targeting CARMA3 for cancer and other diseases. 
 
1.5 Influenza and VSV 
 
Influenza or flu is an infectious disease caused by viruses, which are capable of infecting 
many animals including birds and mammals.  Seasonal influenza virus in humans leads to 
widespread epidemics and is a serious public health problem. For example, the 1918 flu 
pandemic was the most lethal and famous outback. 1918 influenza pandemic lasted from 
1918 to 1919. Although the exact number of people who died from the disease was unknown, 
it was estimated that 50 to 100 million people died during the flu outbreak. The death of 
millions people might be due to the high infection rate and extreme severity of the symptoms, 
which may be caused by virus-induced cytokine storm(Patterson and Pyle 1991). Even in 
modern society, the influenza pandemic endangers people lives. The threat of influenza virus 
to public health urges researchers to better understand influenza virus and its-related host 
immune response, which may facilitate developing the corresponding therapeutic 
interference.  
Influenza virus is RNA virus, which belongs to the family of Orthomyxoviridae. The 
influenza virus is classified into three types, A, B and C. Among them, influenza A virus is 
the most common one and usually causes the most serious problems in humans(Medina and 
Garcia-Sastre 2011). Additionally, our research mainly focused on influenza A virus and its 
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related host immune response. Therefore, in the following sections of this chapter, we will 
mainly focus on influenza A virus. 
Influenza A viruses are negative-sense, single-stranded RNA virus. Its segmented 
genome consists of eight single-stranded negative-sense RNA molecules encoding 11 or 12 
viral proteins.  These viral proteins are nuclear export protein(NS2), the host antiviral 
response antagonist non-structural protein 1(NS1), the matrix protein M1, the ion channel 
M2, the receptor-binding protein haemagglutinin (HA), the sialic acid-destroying enzyme 
neuraminidase(NA), nucleoprotein(NP), the components of the RNA-dependent RNA 
polymerase complex(PB1, PB2 and PA) and N40(Wise, Foeglein et al. 2009, Medina and 
Garcia-Sastre 2011).  
These viral proteins play several roles for virus to complete its life cycle in host cells. 
Specifically,  HA proteins on the viral envelop interact with host cell receptors containing 
terminal α-2,6-linked or α-2-3 linked sialic acid moieties, by which viruses are attached to 
the host cells(Wagner, Matrosovich et al. 2002). Then, HA proteins are cleaved by cellular 
protease to expose HA peptide, which is prerequisite for the fusion between viral envelop 
and the cellular endosomal membrane(Steinhauer 1999). In this way, HA proteins determine 
host tropism and systematic spread, affecting disease severity. When viruses enter cellular 
endosome, the acidification of the vesicles opens the minor virus envelop protein M2, which 
leads to acidification of the core of the virion(Pinto and Lamb 2006, Bouvier and Palese 2008, 
Liu, Zhang et al. 2012). The process is required for uncoating and cytoplasmic release of the 
ribonucleoprotein complex (RNP), where viral RNA genome is wrapped around NP. Then, 
the complex is transported to the nucleus, when the negative-sense viral RNA((-) VRNA) is 
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transcribed and replicated by the RNA-dependent RNA polymerase. During this process, 
three different types of RNA molecules are generated, including the complementary positive-
sense RNA((+)cRNA), negative-sense small viral RNAs(svRNAs) and the viral mRNAs. 
cRNA severs as a template to replicate more vRNA(Cros and Palese 2003). svRNAs play an 
important role in regulating the change from transcription to replication(Perez, Varble et al. 
2010). The viral mRNAs either are transferred to the cytoplasm for the translation of viral 
protein or remain in nucleus.  Some newly synthesized viral proteins are secreted onto the 
cell surface through the Golgi apparatus, such as NA and HA and M2. Some viral proteins 
are transferred into the nucleus to wrap progeny viral genome to form RNP complex for virus 
packaging. Other viral proteins have multiple functions in host cells, including repressing the 
IFN-mediated antiviral response, degrading cellular mRNA, and etc. In plasma membrane, 
the influenza virus M1 protein facilitates the formation of virus particles. Then, budding 
occurs and detaches from cells. The neuraminidase activity of NA is essential for budding, by 
which the SA of the cellular and viral glycoproteins is destroyed. After virus completes its 
life cycle in host cells, the host cells die(Medina and Garcia-Sastre 2011). 
HA and NA not only play crucial roles in virus life cycle but also determine virus 
serotypes.  Until now, 18 known types of HA proteins and 11 known types of NA proteins 
have been identified (Tong, Li et al. 2012). Base on the types of HA and NA protein on the 
surface of the viruses, the influenza A virus are divided into different subtypes. For example, 
H1N1 virus designates an influenza virus subtypes with a type 1 HA protein and a type 5 NA 
proteins. Theoretically, there are possible 198 combinations of HA and NA proteins with 
their corresponding virus subtype. In fact, virus strains circulating in birds are from 16 HA 
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subtypes and nine NA subtypes, while virus strains circulating among humans are H1N1, 
H1N2 and H3N2. H1N1 is responsible for “Spanish flu” and the 2009 swine flu outbreak, 
H2N2 leads to the pandemic of “Asian flu” in the late 1950. H3N2 results in the Hong Kong 
flu in the late 1960s (Air 1981, Nobusawa, Aoyama et al. 1991, Russell, Gamblin et al. 2004, 
Fouchier, Munster et al. 2005). 
Since HA and NA determines serotypes of influenza virus, any change in two proteins 
affects host susceptibility and pathogenesis. Changes in HA and NA proteins occur through 
two different ways. One is antigenic drift, which is characterized by the amino acid changes 
in HA and NA proteins of new virus strains. The antigenic drift is caused by the virus' RNA 
polymerase with no proofreading mechanism, which results in an error rate 
between 1×10−3 and 8×10−3 substitutions per site per year during the replication of viral 
genome replication. Therefore, most of newly synthesized viruses are mutants, which 
partially overcome the protective immunity and are mainly responsible for seasonal influenza 
pandemic. Another way is antigenic shifts, which is characterized by the dramatic change in 
HA subtype. Antigenic shifts help viruses to quickly overcome the protective immunity and 
to infect new host species, leading to the emergence of new pandemics(Medina and Garcia-
Sastre 2011). 
VSV is a negative strand RNA virus too, which belongs to the rhabdovirus family, and 
has been widely used to study the host innate immune response against single strand RNA 
virus. VSV genome is a single molecule of negative-sense RNA with 11,161 nucleotides 
long, encoding five major viral proteins. These viral proteins are nucleoprotein, matrix 
protein(M), phosphoprotein, large protein(L) and G protein(Lichty, Power et al. 2004).  
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Those proteins play several roles in different stages of viral life cycle and facilitate virus 
to complete its life cycle in host cells. Specifically, VSVG is required for viral entry by 
mediating virus attachment to an LDLR family member present on the cell surface. 
Following viral attachment, the VSV-LDLR complex undergoes quick endocytosis, where 
the viral envelope is fused with endosomal membrane and releases viral genome to the 
cytoplasm. In cytoplasm, the virus genome is either replicated with the facilitation of viral 
protein VSV L protein and phosphoprotein or translated for new viral proteins(Finkelshtein, 
Werman et al. 2013).The mature viral protein and new virus genome are packaged into a new 
virus budding from the host cells.  
Since VSVG has a broad host range, VSV is capable of infecting many distinct 
mammalian and nonmammalian cell types. Therefore, VSV can infect many species 
including cattle, horses, pigs, insects and humans. In some cases, it can cause flu-like 
symptom in infected humans (Lichty, Power et al. 2004). Therefore, VSV is a good 
experimental tool for investigating host innate immune responses against RNA virus 
infection. 
   
 
. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1. Antibodies, Plasmids, and Reagents 
 
Antibodies against p-TBK1(Ser172)(#5483), p-IRF3(Ser396 )(#4947), TBK1(#3013), 
RIG-I(#4743), IκBα(#4814) were purchased from Cell Signaling Technology. Antibodies 
against IRF3 (FL-425), BCL10 (H-197), TRAF6 (H-274), ACTIN (#8432, clone C-2), HA 
(sc-805), OctA-probe (D-8) (FLAG: sc-807), were from Santa Cruz Biotechnology. The 
specific CARMA3 antibody was generated by immunizing rabbits with the small peptide 
VRGRILQEQARLVWVEC, matching to the C terminus of human and mouse CARMA3. 
Then, the antibody was purified by the same peptide-conjugated columns. The MAVS 
antibody was a kind gift from Dr. Zhijian "James" Chen’s Lab. NF-κB or OCT-1binding-
site-specific probes were obtained from Promega. TRIzol reagent (15596-026), 
Lipofectamine 2000 Transfection Reagent (11668-019), Superscript III First-Strand 
Synthesis system (18080-051) were obtained from Invitrogen. Fast SYBR Green Master Mix 
was purchased from Applied Biosystems (4385612). Mouse IFN Beta ELISA Kit was 
obtained from PBL Assay Science (42400-2)  , while Mouse IL-6 ELISA Ready-SET-Go KIT 
was purchased from Affymetrix bioscience(88-7064-86). Poly (I:C) LMW(tlrl-picw-250), 
5'ppp-dsRNA(tlrl-3prna-100) and 5ppp-dsRNA control(tlrl-3prna) were purchased from 
InvivoGen. Influenza A/PR/8/34(H1N1) was purchased from Charles River. NF-κB 
Inhibitors (213546-53-3), polybrene (sc-134220) was obtained from Santa Cruz.  
Cycloheximide was purchased from Sigma (C7698).  PCMV-Tag4-CARMA3 and its 
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derivatives (CD-CC, ∆CD-CC, ∆SH3-GUK, ∆GUK) that encode Flag-tagged CARMA3 WT 
or mutants have been described previously (Sun and Lin 2008). RIG-I, IKKε, MAVS and 
TBK1 plasmids were obtained from Addgene. Myc-tagged BCL10 has been described 
previously (Blonska, Pappu et al. 2007). shRNA against GFP, CARMA3 or BCL10 were 
obtained from Sigma. 
 
2.2. Cell Cultures 
WT, CARMA3 deficient, BCL10 deficient and MALT1 deficient mouse embryonic 
fibroblasts (MEF) cells were isolated from mouse embryos from corresponding knockout 
mice and prepared as previously described (Grabiner, Blonska et al. 2007). MEF cells, 
human neuroblastoma SKNAS cells and human lung adenocarcinoma epithelial A549 cells 
were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal 
bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin. MEF cells were grown in 
8.5% CO2 at 37°C and passaged every three days. SKNAS and A549 cells were grown in 5% 
CO2 at 37°C and passaged every two days. 
 
2.3. Electrophoretic Mobility Shift Assay (EMSA) 
 
Nuclear extraction and EMSA were performed as described previously (Grabiner, 
Blonska et al. 2007). Briefly, nuclear extracts were isolated from 1×106 cells stimulated for 
appropriate times with different agents. Then, nuclear extracts (1–10 µg) were incubated with 
32P-labeled NF-κB and OCT-1 probes at room temperature for 15 minutes. After incubation, 
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the mixed samples were loaded into a native 10% acrylamide gel (1×Tris-borate-EDTA) and 
run for 85 minutes at 220V. The gels were dried in a vacuum gel drying system and then 
exposed to X-ray film. 
 
2.4. Western Blotting and Immunoprecipitation 
 
Various types of cells were lysed in a lysis buffer containing 50 mM HEPES (pH 7.4), 
150mM NaCl(or in the range of 50–250 mM NaCl), 1 mM EDTA, 1% NP-40, 1 mM 
Na3VO4, 1mM PMSF, 1 mM NaF, 1mM DTT, and 1×protease inhibitor cocktail (Roche 
Diagnostics). The cell lysates were subjected with immunoblotting by the indicated 
antibodies or immunoprecipitated with various antibodies-conjugated beads. For 
immunoprecipitation, the antibodies-conjugated beads were incubated with the cell lysate 
overnight at 4˚. After incubation, the beads were washed with cold 1×PBS. Then, the 
precipitates were eluted by 2×loading buffer and were subjected to SDS-PAGE and 
immunoblot. 
 
2.5. Quantitative RT-PCR (qRT-PCR) 
 
Total RNA isolation was isolated using TRIzol reagent (Invitrogen) according to the 
manufacturer's instructions. Reverse transcription was performed by the SuperScriptIII First-
Strand Synthesis System with 1 µg of total RNA according to the manufacturer's instructions 
with 50 µM oligo(dT) or random hexanucleotides. Then, qRT-PCRs were performed using 
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the cDNA with gene-specific oligonucleotide primers (10 pM each). The primers used are 
listed in Table 2. 
 
2.6. Lentivirus Infection for shRNA Knockdown 
 
 Lentivirus encoding control shRNA, CARMA3 shRNA and BCL10 shRNA was 
generated as previously described (Jiang, Grabiner et al. 2011). Briefly, HEK 293 cells were 
transfected with Lentivirus plasmids with packaging vectors encoding VSV-G and Dr.82 to 
generate viruses. At 12 hours after transfection, the supernatant was replaced with the fresh 
medium. The supernatant was collected from the HEK 293 cells at 48 hours after transfection 
and centrifuged at 2000×g for 10 minutes to get rid of any cell debris. Then, the supernatant 
was incubated with target cells for infection in presence of 8 µM polybrene overnight. One 
day after virus infection, the infectious medium was replaced with media containing 1 µg/ml 
puromycin for the selection. Four days after puromycin selection, the resultant pools were 
used for experiments. 
 
2.7. Semidenaturing Detergent Agarose Gel Electrophoresis(SDD-AGE) 
 
 SDD-AGE was performed as previously described (Hou, Sun et al. 2011). In brief, 
crude mitochondrial were isolated from cells stimulated for appropriate time with various 
reagents. Then, the crude mitochondrial were resuspended in 1×sample buffer containing 
0.5×TBE, 10% glycerol, 2% SDS, and 0.0025% bromophenol blue.  The mixed samples 
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were separated in a vertical 1.5% agarose gel in the running buffer (1×TBE and 0.1% SDS) 
for 35 min with a constant voltage of 100 V on ice. After running, the proteins were 
transferred to nitrocellulose membranes (Bio-Rad) for immunoblotting by indicated 
antibodies. 
 
2.8. VSV and Influenza virus mouse model 
 
 Groups of six 4–6 weeks old WT and CARMA3 or BCL10 deficient mice were 
intranasally inoculated with 20 µl of  H1N1 influenza virus at pfu=600 in PBS under 
isofluorane sedation. Mice survival and body weight were measured daily until 14 days post-
infection (dpi). Moribund mice were considered as losing body weight >20% of their initial 
or exhibiting severe disease. Moribund mice were humanely sacrificed.  
 Groups of 4–6 weeks old WT and CARMA3 or CARMA1 mice were intranasally 
inoculated with 20 µl of VSV at pfu=1×107 in PBS under isofluorane sedation. Mice serum 
was harvested at 24 hours after infection, while different tissues (lung, brain and spleen) were 
harvested at 2 days after infection.  
 
2.9. Influenza TCID50 Assay 
 
 MDCK cells were cultured in high glucose DMEM containing 10% FBS and 1% 
Pen-Strep in a T75 at 37oC. One day before TCID50 assay, 2×103 cells were seeded in 96 well 
plates with 150µL of medium. In next day morning, influenza samples were thawed and 
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homogenized on ice with 600µl medium, which was transferred into the 1st tube of the 
dilution series and then serially dilute 184 µL across the tubes on ice. 100 µL of diluting 
sample was incubated with cells at 37oC for 1 hour in the presence of 1ug/ml TPCK treated 
trypsin. After incubation, the infectious medium was replaced with fresh 150uL DMEM with 
1µg/ml TPCK treated trypsin. After 3 days of incubation, the medium was aspirated off and 
replaced with 200 uL of a crystal violet working stock (40 mL 1% Crystal Violet, 80 mL 
Methanol, 300 mL H2O).  Cells were stained with crystal violet working stock for 1 hour and 
rinsed with tap-water.   
 
2.10. Luciferase Reporter Assay 
 
Luciferase assays were performed as described previously (44). In brief, HEK 293 cells 
were seeded in triplicates in 12-well plates and transfected with 100 ng of NF-κB-responsive 
luciferase and IFNβ promoter-dependent luciferase constructs encodes the firefly luciferase 
and 10 ng of EF1α promoter-dependent Renilla luciferase reporter together(as a transfection 
control) with 1.5 µg of expression vectors for different proteins or vector controls. At 16 
hours after transfection, the cells were harvested and lysed to detect luciferase activities by 
dual-luciferase kit (Promega). 
 
2.11. VSV plaque assay 
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 The medium containing virus was diluted with DMEM and prepared for VSV 
plaque assay. The tissue samples were homogenized and the supernatant was used for VSV 
plaque assay. The VSV plaque assay protocol was previously described. Briefly, at 1 hour 
after infection, the infectious medium in cells was replaced with complete medium 
containing 0.5% methylcellulose (Sigma-Aldrich) for 48 hrs. Then, BHK cells were fixed in 
fixation solution and stained with crystal violet working solution. Virus titers were expressed 
as PFU per milliliter, which counts the plaques in well. VSV plaque assay for each sample 
was triplicated, and the averages of the virus titers were calculated. 
 
2.12. Isolation of crude mitochondria 
 
 Crude mitochondrial was isolated as described previously (Hou, Sun et al. 2011). 
Briefly, cells simulated with appropriate reagents for indicated time were washed with ice-
cold PBS twice and harvested by centrifuging at 600g for 3 minutes. Hypotonic buffer was 
used to swell the cells for 2.5 minutes at 4°C. Hypotonic buffer contains 10mM KCl, 0.5mM 
EGTA, 10mM Tris-Cl, pH7.5, 1.5mM MgCl2, 1mM PMSF, and 1x EDTA-free protease 
cocktail. Then, the swollen cells were homogenized for 40 strokes in a tight-fitting Douncer 
Homogenizer at 4°C. The supernatant was centrifuged at 600g for 5 minutes to remove the 
insoluble parts. The resulting supernatant was centrifuged at higher speed to collect the 
mitochondria. The crude mitochondria was resuspended in mitochondria resuspend buffer 
(MRB) ,containing 0.5mM EGTA, 1mM PMSF, 20mM HEPES-KOH, pH7.4, 1x EDTA-free 
protease cocktail, 0.8M sucrose and then, centrifuged at 7,000g for 10 minutes. The pellet 
  
33 
 
was resuspended and centrifuged again. The resulting pellet was resuspended in MRB buffer 
with 2% CHAPs and was incubated in ice bath for 15 min.  The mitochondria lysates were 
mixed with 2X loading dye (1 × TBE, 10% glycerol, 4% SDS, and 0.005% bromophenol 
blue) containing no reduction reagents.  
 
2.13. Bone marrow-derived macrophage (BMDM) preparation. 
 
Primary cultures of BMDMs from WT or CARMA1 deficient mice were isolated from 
tibias and femurs of WT or CARMA1−/− mice as previously described (Bi, Gojestani et al. 
2010, Gorjestani, Yu et al. 2011). In brief, after isolation, the mix cells were incubated in 
hypotonic solution for 10 minutes to get rid of erythrocytes.  The resulting  cells were 
cultured in DMEM containing 20% FBS, 55 µM β-mercaptoethanol, 100 µg/ml streptomycin, 
100 U/ml penicillin, and 30% conditioned media from L929 cells expressing macrophage 
CSF (M-CSF) for 7 days.  At 3 days after isolation, the medium was replaced with the fresh 
one to remove non-adherent cells. After 1 wk of cultures, cells was stained with 
combinations of fluorescence-conjugated monoclonal antibodies (CD11b+ and F4/80+) and 
analyzed by flow cytometry to assess the cellular purity. Cell population contained 86–95% 
CD11b+ F4/80+cells. 
 
2.14. Splenocyte Isolation and Staining 
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Splenocytes were isolated from the spleen of different types of mice. Briefly, the spleens were 
transferred into the cell strainer in the Petri dish and washed with 1ml pre-cold PBS. The spleen was 
mashed by the black rubber end of 2ml syringe to relase the splenocytes into the Pertri dish. The 
homogenized cell suspension was transferred to a new tubes and was collected by centrifuge at 400×g 
for 10 minutes. The resulting cells was washed with 1ml pre-cold PBS once and were incubated with 
hypotonic solution for 15 minutes to get rid of erythrocytes. The resulting cells were washed with 
PBS again and were ready to stain with the fluorescence-conjugated monoclonal antibodies(CD11c+). 
 
2.15. Stable isotope labeling by amino acids(SILAC) experiments 
All SILAC experiment-related reagents were bought from Pierce (Thermo Scientific). SILAC-
DMEM medium deficient in lysine and arginine were supplemented with L-lysine, L-arginine, 10%  
dialyzed fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin. HEK 293T 
cells expressing empty vector were cultured in the “light” medium supplemented with Lys0 (12C6) 
and Arg0 (12C6), while HEK293T cells transiently expressing CARMA3-FLAG were culture in the 
‘heavy’ culture with Lys8 (13C6) and Arg10 (13C6).  48 Hours after transfection, cells were lysed 
in a lysis buffer containing 50 mM Tris (pH 7.4), 150mM NaCl, 1 mM EDTA, 2% DDM, 
and 1×protease inhibitor cocktail (Roche Diagnostics). The same amounts of cell lysates of 
more than 1 mg were immunoprecipitated with FLAG antibodies-conjugated beads. The 
proteins-bead were washed 3 times with cold lysis buffer. The proteins were eluted with 
FLAG peptides(100µg/ml) and merged together before subjecting to SDS-PAGE and silver 
staining. Then, gel slices from SDS-PAGE lanes were excised and digested with trypsin. Peptides 
generated by protease digestion were fractionated on a analytical column (75 µm ID, 100 mm in 
length) packed with C18 resin by Dionex Ultimate 3000 nanoLC system (Thermo Scientific). The 
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column was coupled in-line to a Q Exactive mass spectrometer (Thermo Scientific) equipped with a 
nano-electrospray ion source. MS/MS spectra (resolution: 17,500 at m/z = 200) were acquired in a 
data-dependent mode, whereby the top 15 most abundant parent ions were subjected to further 
fragmentation by higher energy collision induced dissociation (CID). MS raw data was searched 
against Swissprot database(Homo Sapiens)  using mascot searching engine and was quantified with 
mascot distiller. The MS tolerance was set to 15 ppm, and the MS/MS tolerance was set to 20 mmu. 
To define a reliable peptide, the score should exceed the identity threshold given by Mascot, 
meanwhile, the false discovery rate (FDR) at protein levels was set to 0.01. For the quantification of 
the identified proteins, Mascot Distiller software (Version 2.5.1.0) was used to calculate the ratios 
between the heavy- and light-labeled IP products (H/L) at both peptides and proteins level. For the 
quality control, the threshold of standard error for each XIC pair was set to 0.1, and the threshold of 
correlation coefficient between the predicted and observed precursor isotope distributions was set to 
0.7. Only peptides exceeding the homology threshold were used for the quantification. 
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CHAPTER 3:  RESULTS 
 
 
3.1.CARMA3 deficiency caused mouse to be more resistant to influenza infection. 
 
Using collaborative cross (CC) mouse model of influenza infection, the researchers found 
that genetic variations in CARMA3 regulated differential response phenotypes to influenza 
infection(Ferris, Aylor et al. 2013). However, the role of CARMA3 in influenza infection 
remains largely unknown. To confirm the important role of CARMA3 in influenza infection, 
we infected WT and CARMA3 deficient mice with H1N1 influenza virus at pfu=600. Then, 
we measured the change of mice bodyweight daily until 14 days after virus infection. We 
found that WT mice lose more body weight than CARMA3 deficient mice until the end of 
experiments (Fig.5A).  Next, we decided to detect the virus replication in mice. The WT, 
CARMA3+/- and CARMA3 deficient mice were intranasally injected with influenza at 
pfu=500. Two days later, we harvested the lungs from mice. The influenza virus titer in lungs 
was measured by tissue culture infectious dose (TCID50) assays. We found that there was less 
virus titer in lungs from CARMA3 deficient mice than that from WT or CARMA3 Het mice. 
It might explain why WT mice losed more body weight than CARMA3 deficient mice during 
the experiments (Fig.5B). These data suggested that CARAM3 deficiency caused mice more 
resistant to influenza infection.  
After influenza virus infection, its RNA genome is recognized by PRRs to trigger the 
production of proinflmmatory cytokines and type I IFNs(Medina and Garcia-Sastre 2011). 
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Among them, IL6 and IFNβ are the important cytokines. The transcription of IL6 is 
controlled by transcription factor NF-κB, while the expression of IFNβ is mainly mediated 
by the transcriptional factor IRF3 (Sato, Suemori et al. 2000, Xiao, Hodge et al. 2004, Honda, 
Yanai et al. 2005). The lung and serum were harvested from the infected mice 3 days after 
infection. The level of serum IL6 and lung IFNβ were measured by ELISA and qRT-PCR, 
respectively. We found that CARMA3 deficient mice had more lung IFNβ but less the serum 
IL6 after virus infection (Fig.6). 
 
3.2.CARMA3 deficiency caused mice to be resistant to VSV infection. 
 
VSV also is a negative single-stranded RNA virus. To check whether CARMA3 
contributes to the variable host responses to RNA virus infection, we challenged WT and 
CARMA3 deficient mice intranasally with VSV-GFP at 1×107 pfu. We harvested serum and 
tissues at 24 hrs and 48 hrs after infection, respectively. The virus titer in different tissues 
was measured by viral plaque assay. The level of serum IL6 and IFNβ were measured by 
ELISA. There was less virus titer in the CARMA3 deficient mice than that in WT mice in 
different tissues including spleens, olfactory bulbs (OB) and lungs, which suggested the 
negative role of CARMA3 in VSV infection in vivo(Fig.7). Next, we decided to check the 
level of serum IL6 and IFNβ. Surprisingly, the level of serum IL6 and IFNβ was comparable 
between WT and CARMA3 deficient mice. Since the CARMA3 is only expressed in non-
hematopoietic tissues, we decided to further check the local IFNβ and IL6 production by 
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qPCR in OB(Jiang and Lin 2012). We found that there was more IFNβ in the OBs from 
CARAM3 deficiency mice than those from WT mice (Fig.8).  
To check the negative role of CARMA3 in VSV infection in vitro, we infected primary 
WT and CARMA3 deficient MEF cells with VSV at MOI=10.  One hour after infection, the 
infectious medium was replaced with fresh medium to get rid of uninfected virus. At 24 hrs 
after infection, we measured the virus titer in supernatant using viral plaque assay. We found 
that there was less viral titer in supernatant from CARAM3 deficient cells than that from WT 
cells.  Next, we obtained lentivirus constructions encoding control shRNA and CARMA3 
shRNA, which significantly inhibited CARMA3 mRNA transcription. We infected different 
cell lines, such as A431, Hela with lentivirus construction encoding control shRNA or 
CARMA3 shRNA. Then, we examined the virus titer from supernatant using the protocol as 
described previously. We found that there was less viruses in the supernatant from CARMA3 
knockdown cells than that from control knockdown cells (Fig.11). It suggested that 
CARMA3 deficiency or knockdown caused cells more resistant to VSV infection. 
 
3.3. The activation of NF-κB signaling pathway was reduced in CARMA3 
deficient cells after VSV infection. 
 
It was found that the CARMA3 was required for NF-κB activation induced by some 
GPCRs and receptor tyrosine kinases in non-hematopoietic tissues (Grabiner, Blonska et al. 
2007, Klemm, Zimmermann et al. 2007, McAllister-Lucas, Ruland et al. 2007, Mahanivong, 
Chen et al. 2008). To determine whether CARMA3 was involved in VSV-induced NF-κB 
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activation, we first infected WT and CARMA3 deficient MEF cells with VSV at MOI=3.  
We detected the activation of NF-κB signaling pathway by EMSA at different time points. 
We found the activation of VSV-induced NF-κB was decreased in CARMA3 deficient MEF 
cells, compared to WT cells. It suggested that CARMA3 played a positive role in VSV-
induced NF-κB activation (Fig.9A). To further confirm the positive role of CARMR3 in 
VSV-induced NF-κB activation, we decided to check the production of IL6 in WT and 
CARAM3 deficient MEF cells upon VSV infection, since the transcription of IL6 is 
controlled by NF-κB (Xiao, Hodge et al. 2004). The level of IL6 was measured at 6,12 hours 
after virus infection by both qPCR and  ELISA. We found there was less production of IL6 in 
CARAM3 deficient MEF cells than that in WT cells (Fig.9 B&C).  
 
3.4. CARMA3 deficient cells increased IFN-β production after VSV infection. 
 
IFNβ secreted by cells plays an important role in inhibiting virus infection(Schneider, 
Chevillotte et al. 2014). Since previous data showed that tissues in CARMA3 deficient mice 
produced more IFNβ after virus infection, we decided to detect the production of IFNβ in 
cells after virus infection.  WT and CARMA3 deficient MEF cells were infected with VSV at 
MOI=3. At the different time points, the production of IFNβ was measured by qPCR or 
ELISA. We found that CARMA3 deficient cells produced more IFNβ after virus infection, 
compared to WT cells (Fig.10 A&B). 
It has been established that the production of IFNβ was controlled by TBK1-IRF3 
signaling pathway. Since there was increased production of IFNβ in CARMA3 deficient cells 
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after VSV infection, we decided to check the activation of TBK1-IRF3 signaling pathway in 
different cell types after virus infection. The WT and CARMA3 deficient MEF cells were 
infected with VSV at MOI=3. The activation of TBK1-IRF3 signaling pathway was 
measured by immunoblotting using specific p-TBK1 (Ser 172) and p-IRF3 (Ser 396) 
antibodies. We found that the phosphorylation of TBK1 and IRF3 were increased in 
CARMA3 deficient MEF cells. It suggested that the activation of TBK1-IRF3 signaling 
cascade was enhanced in CARMA3 deficient cell (Fig.10C). These data suggested that 
CARMA3 played a negative role in the virus-induced activation of TBK1-IRF3 signaling 
pathway.   
 
3.5 CARMA3-deficient MEF cells had decreased activation of NF-κB signaling 
pathway and thereby, produced less IL6 after poly(I:C) transfection. 
 
Both VSV and influenza are ssRNA viruses. When they infect cells, their RNA genome 
are recognized by both TLR3 and RIG-I(Jacobs and Coyne 2013). To specify the role of 
CARMA3 in RIG-I/MAVS signaling pathway, we decided to transfect cells with specific 
ligands of the RIG-I/MAVS signaling pathway such as poly (I:C) and 5’ppp-dsRNA. Poly 
(I:C) is a synthetic analog of dsRNA, a PAMP associated with RNA virus infection. Naked 
poly(I:C) is recognized by TLR3 on the cell surface(Lester and Li 2014). However, when 
poly (I:C) is transfected into cells, it can be specifically recognized by cytoplasmic RIG-I and 
MDA5 receptors in a cell-dependent manner(Kato, Sato et al. 2005, Gitlin, Barchet et al. 
2006). WT and CARAM3 deficient MEF cells were transfected with 1 ug/ml poly(I:C) by 
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lipotofactamine 2000. We measured the activation of NF-κB by EMSA and the production of 
IL6 by qPCR and ELISA.  Both the activation of NF-κB and the production of IL6 were 
decreased in CARMA3 deficient cells after poly(I:C) transfection at the different time points. 
It suggested the positive role of CARMA3 in RIG-I/MAVS-mediated NF-κB signaling 
pathway (Fig.12). 
 
 
3.6 CARMA3-deficient MEF cells had increased activation of IRF3 signaling 
pathway and thereby, produced more IFNβ after poly (I:C) transfection. 
 
WT and CARMA3 deficient MEF cells were transfected with poly (I:C) with 
lipotofactamine 2000. The activation of TBK1-IRF3 signaling pathway was measured by 
immunoblotting using the specific p-IRF3 (Ser396) antibodies. We found that IRF3 signaling 
pathway was activated in WT cells after poly (I:C) transfection, but the activation was 
increased  in CARMA3 deficient MEF cells (Fig.13D). Consistently, the production of type I 
IFNs in CARAM3 deficient MEF was more than that in WT cells after poly(I:C) transfection. 
It suggested that CARMA3 negatively regulated RIG-I-mediated TBK1-IRF3 signaling 
pathway (Fig.13 A, B and C). 
 
3.7 CARMA3-deficient MEF cells produced less IL6 but more IFNβ after dsRNA 
transfection. 
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To verify the role of CARMA3 in RIG-I/MAVS signaling pathway, we decided to use 
another specific ligand: 5' ppp-dsRNA. 5' ppp-dsRNA is a synthetic ligand specific for RIG-I. 
The WT and CARMA3 deficient MEF cells were transfected with 1ug/ml 5' ppp-dsRNA by 
lipofectamine 2000. We measured the production of type I IFNs and IL6 by qPCR and 
ELISA.  We found that CARMA3 deficiency impaired 5' ppp-dsRNA-induced IL6 
production (Fig.14). On the other hand, CARMA3-deficient cells produced more type I IFNs 
after ligand transfection (Fig.15). Together, these data suggested the dual role of CARMA3 
in RIG-I/MAVS-mediated activation of NF-κB and IRF3 signaling pathways. Specifically, 
CARMA3 played a positive role in RIG-I/MAVS-mediated NF-κB signaling pathway, but a 
negative role in TBK1-IRF3 signaling pathway. 
 
3.8 BCL10 deficient cells had decreased activation of NF-κB signaling pathway, but 
increased activation of TBK1-IRF3 signaling pathway after virus infection and poly 
(I:C) transfection. 
 
Previous studies demonstrated that CARMA3 interacted with BCL10 and MALT1 to 
form CBM complex, which regulated the activities of IKK complex through mediating 
NEMO-associating polyubiquitination (Grabiner, Blonska et al. 2007).  Therefore, we 
hypothesized that BCL10 is involved in RIG-I-mediated NF-κB activation. To test the 
hypothesis, we treated WT and BCL10 deficient MEF cells with VSV infection or poly (I:C) 
transfection. The production of IL6 was measured by both qPCR and ELISA. We found that 
BCL10 deficiency impaired both virus infection and poly (I:C) transfection-induced IL6 
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production (Fig.18). It suggested that BCL10 played a positive role in RIG-I /MAVS-
mediated NF-κB signaling pathway, which was similar to CARMA3. 
Next, we decided to test the role of BCL10 in RIG/MAVS-mediated TBK1-IRF3 
signaling pathway. We treated WT and BCL10 deficient MEF cells with VSV infection and 
poly (I:C) transfection. We detected the activation of TBK1-IRF3 signaling pathway and the 
production of type I IFNs, using the methods as described previously.BCL10 deficiency 
caused cells to produce more type I IFNs after both VSV infection and poly(I:C) transfection. 
Consistently, the activation of TBK1-IRF3 signaling pathways was enhanced in BCL10-
deficienct cells after treatments. It suggested that BCL10 played a negative role in the 
activation of RIG-I/MAVS-mediated TBK1-IRF3 signaling pathway, which is similar to 
CARAM3 (Fig.17). 
To further demonstrate the role of CARMA3 and BCL10 in RIG-I/MAVS signaling 
pathways, we obtained three different lentivirus constructions encoding control shRNA, 
CARAM3 shRNA and BCL10 shRNA. We infected A549 cells with different lentiviruses to 
significantly suppress the expression of CARMA3 or BCL10.  We compared the activation 
of NF-κB and IRF3 signaling pathway among cells stably expressing control shRNA, 
CARMA3 shRNA and BCL10 shRNA upon VSV infection or poly (I:C) transfection. Cells 
with control knockdown produced IL6 and IFNβ after VSV infection or poly (I:C) 
transfection, whereas cells with CARMA3 or BCL10 knockdown produced more IFNβ, but 
less IL6 after treatments(Fig.20). Consistently, the activation of TBK1-IRF3 signaling 
pathway was enhanced in cells with CARMA3 or BCL10 shRNA, compared to cells with 
control knockdown (Fig.19). 
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3.9 BCL10 deficiency caused mice to be more resistant to VSV infection. 
 
Our previous data suggested that CARMA3 deficiency led to mice more resistant to VSV 
infection. Since BCL10 always functions together with CARAM3 to form a complex, we 
hypothesized that BCL10 deficiency also causes mice to be more resistant to VSV infection 
(Grabiner, Blonska et al. 2007). Groups of 6-8 weeks WT and BCL10 deficient mice were 
intranasally injected with VSV-GFP at pfu=1×107. The virus titer in different tissues was 
measured by viral plaque assay.  WT mice had more virus titer in different tissues than 
BCL10 deficient mice did. It suggested that BCL10 deficiency caused mice to be more 
resistant to VSV infection, which is similar to CARAM3 deficient mice (Fig.21). 
Together, our data suggested that BCL10 functioned as a partner with CARMA3 to 
regulate RIG-I/MAVS-mediated signaling pathways.  
 
3.10 MALT1 deficiency did not impair VSV infection or poly (I:C) 
transfection-induced NF-κB activation. 
 
Previous study showed that MALT1 was an important component of CBM complex, 
which regulated NF-κB signaling pathway through IKK complex (Grabiner, Blonska et al. 
2007). Therefore, we hypothesized that MALT1 contributes to VSV-induced NF-κB 
activation. We treated WT and MALT1 deficient MFE cells with VSV infection. We found 
that the activation of NF-κB and the production of IL6 were comparable between two cells 
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types after virus infection (Fig.22C& Fig.23). It suggested that MALT1 deficiency did not 
impair RIG-I/MAVS-mediated NF-κB activation.  
 
3.11 MALT1 deficiency did not enhanced VSV or poly (I:C) transfection-
induced IRF3 activation. 
 
Our previous data showed that both CARMA3 and BCL10 play a negative role in VSV 
infection and poly (I:C) transfection-induced IRF3 activation. Additionally, MALT1 always 
forms a complex with CARMA3 and BCL10 in context of NF-κB signaling pathway. 
Therefore, we hypothesized that MALT1 plays a negative role in RIG-I/MAVS-mediated 
IRF3 activation. To test the hypothesis, we infected the WT and MATL1 deficient MEF cells 
with VSV. We measured the activation of TBK1-IRF3 signaling pathway and the production 
of type I IFNs according to protocols previously described. We found the activation of IRF3 
signaling pathway and the production of type I IFNs were comparable between WT and 
MALT1 deficient MEF cells(Fig.22 A and B& Fig. 24). It suggested that MALT1 did not 
play a role in RIG-I/MAVS-mediated IRF3 activation. 
 
3.12 The inhibition of NF-κB signaling pathway did not enhance the activation 
of IRF3. 
 
Both NF-κB and IRF3 are transcription factors. When they are active, they enhance 
expression of genes in response to different stimulus(Oeckinghaus and Ghosh 2009). 
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Additionally, based on our data, we found that NF-κB signaling pathway acted prior to 
TBK1-IRF3 signaling pathway. Therefore, we hypothesized that NF-κB target genes inhibit 
the activation of IRF3. To test the hypothesis, we pretreated the primary MEF with NF-κB 
inhibitors and then infected the cells with VSV at MOI=3. The NF-κB inhibitor is a small 
peptide, which specially targets the nuclear translocation signals in p50 and thereby, blocks 
the nuclear translocation of the active NF-κB dimmers. The activation of NF-κB signaling 
pathway was measured by EMSA, while the activation of IRF3 was measured by 
immunoblotting using specific p-IRF3 antibody.  NF-κB signaling pathway was activated by 
VSV infection at different time points, whereas the activation was partially blocked by the 
treatment of NF-κB inhibitor. It suggested that the NF-κB inhibitor worked well in the 
experiments. On the other hand, the IRF3 was phosphorylated at different time points after 
VSV infection. However, the IRF3 phosphorylation was not enhanced with the treatment of 
NF-κB inhibitor during VSV infection. It suggested that NF-κB target genes did not inhibit 
IRF3 activation (Fig.25). In other words, crosstalk between NF-κB and IRF3 signaling 
pathway was not critical for the increased activation of IRF3 signaling pathway in CARMA3 
deficient cells. 
 
3.13 The inhibition of new protein synthesis did not rescue the enhanced 
activation of TBK1-IRF3 signaling pathway in CARAM3 deficient cells 
 
To further confirm it, we decided to pretreat primary MEF cells with 10 µg/ml 
  
47 
 
cycloheximide (CHX) to block new protein synthesis. Then, cells were transfected with 
1µg/ml poly (I:C) by lipofectamine 2000. At the different time points, the activation of IRF3 
was measured by immunoblotting using specific p-IRF3 antibody. Compared to WT MEF 
cells, the phosphorylation of IRF3 was increased in CARMA3 deficient MEF cells. The 
enhancement cannot be blocked by CHX treatment. It suggested that CARMA3 and BCL10 
directly regulated RIG-I/MAVS-mediated signaling pathways, not through the secondary 
effect (Fig.26). 
 
3.14 In RIG-I/MAVS signaling pathway, CARAM3 worked together with 
MAVS. 
 
Our previous data suggested that CARMA3 and BCL10 were directly involved in RIG-
I/MAVS signaling pathways. Next, we decided to investigate how CAMRA3 and BCL10 
regulated IRF3 or NF-κB signaling network. To do that, we infected HEK 293 cells with 
lentivirus encoding control shRNA, CARMA3 shRNA or Bcl10 shRNA. Then, we 
overexpressed MAVS-FLAG in those cells together with NF-κB-responsive luciferase 
construct or IFNβ luciferase reporter plasmids. The overexpression of MAVS could activate 
both NF-κB and IRF3 signaling pathways in cells with control knockdown. There is 
hyperactivation of IRF3 and hypoactivation of NF-κB in cells with CARMA3 or BCL10 
knockdown. It suggested that CARMA3 and Bcl10 worked together with MAVS (Fig.27A). 
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3.15 In MAVS/RIG-I signaling pathway, CARAM3 worked upstream of 
TBK1 and IKKε 
 
Next, we overexpressed TBK1-FLAG or IKKε-FLAG in HEK 293 cells stably 
expressing control shRNA, CARMA3 shRNA or BCL10 shRNA, together with NF-κB-
responsive luciferase constructs or IFNβ luciferase reporter plasmids.  Overexpression of 
TBK1-Flag induced the activation of both NF-κB and IRF3 signaling pathway in cells with 
control knockdown, while the activation of these two signaling pathways was comparable in 
cells with CARMA3 and BCL10 knockdown. When it came to IKKε overexpression, we 
found the similar results. It suggested that CARMA3 worked upstream of TBK1 and IKKε in 
MAVS/RIG-I signaling pathway (Fig.27 B, C&D). 
Together, our data suggested that CAMRA3 worked downstream of MAVS, but 
upstream of TBK1 and IKKε. 
 
3.16 CARMA3 interacted with MAVS. 
 
Similar to CARMA3, MAVS and RIG-I proteins contain CARD domain. It was 
established that CARD domain was important for the interaction between CARD-domain 
containing proteins(Blonska and Lin 2011). Additionally, our previous data showed that 
CARMA3 worked downstream of MAVS. Therefore, we hypothesized that CARMA3 
interacts with MAVS. To test the hypothesis, we decided to firstly detect the interaction 
between CARMA3 and MAVS, when they are overexpressed in HEK 293 cells. We 
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overexpressed CARMA3-HA with MAVS-FLAG or RIG-I-FLAG in HEK 293 cells. At 24 
hours after transfection, we immunoprecipitated(IP) MAVS or RIG-I using anti-Flag 
antibody conjugated beads. The immunoprecipitated complex and cell lysates were subject to 
immunoblotting using indicated antibodies. We found that both CARMA3 and BCL10 
interacted with MAVS, while BCL10 not CARMA3 was associated with RIG-I (Fig.28A). 
To further confirm MAVS’s interaction with CARMA3, we decided to check the 
endogenous interaction between CARMA3 and MAVS. We infected immortalized CARMA3 
deficient MEF with lentivirus constructions encoding CARMA3-HA. Then, we infected cells 
stably expressing CARMA3-HA with VSV at MOI=3. At different time points, we 
immunoprecipitated CARMA3-HA using specific anti-HA antibody-conjugated beads or 
control anti IgG-conjugated beads. The immunoprecipitated complex and cell lysates were 
subject to immunoblotting using indicated antibodies. We found that CARMA3 inducibly 
interacts with MAVS and BCL10 at 3 and 4 hours after virus infection (Fig.29A). 
Besides, we found that CARMA3 was cleaved after virus infection. The immortalized 
CARMA3 deficient cells stably expressing CARMA3-HA were infected with VSV at 
MOI=3. We detected two bands at 3 hours after virus infection using anti-HA antibody. The 
upper band was decreased, while the lower band was increased during virus infection. To 
confirm the cleavage of CARMA3, we used specific anti-CARMA3 antibody, which raised 
against the small peptides from both N-terminal and C-terminal of protein. We detected one 
lower cleaved band. It suggested that CARMA3 was cleaved in the middle of protein 
(Fig.29A). 
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3.17 BCL10 interacted with MAVS and RIG-I. 
 
Next, we decided to check the interaction between BCL10 and MAVS. We firstly 
overexpressed BCL10-MYC and MAVS-FLAG or RIG-I-FLAG in HEK 293 cells and then 
immuniprecipitated MAVS or RIG-I using anti-FLAG antibody conjugated beads. The 
immunoprecipitated complex and cell lysates were subject to immunoblotting with the 
indicated antibodies. We found that Bcl10 interacted with both MAVS and RIG-I, when they 
were overexpressed (Fig.28B). 
To further confirm the interaction between MAVS and BCL10, we decided to detect the 
endogenous interaction between two proteins. The HEK 293 cells were transfected with 
1µg/ml poly (I:C) by lipofectamine 2000. At the different time points, we 
immunoprecipitated BCL10 and detected its interaction with MAVS. We found that BCL10 
inducibly interacted with MAVS at 1 hour after poly (I:C) transfection. We cannot see the 
interaction between BCL10 and MAVS at 2 and 3 hours after poly (I:C) 
transfection(Fig.29B).  
 
3.18 CARMA3 and BCL10 competed with RIG-I in binding with MAVS 
 
  It was found that RIG-I interacted with MAVS and triggered MAVS to form prion-
like structure after virus infection (Hou, Sun et al. 2011). Our previous data showed that 
CARMA3 and BCL10 interacted with MAVS. Therefore, we hypothesized that CARMA3 or 
BCL10 competes with RIG-I in binding with MAVS. To test the hypothesis, we 
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overexpressed MAVS-His and RIG-I-FLAG in presence of CARMA3-HA or BCL10-Myc in 
HEK 293 cells. At 24 hours after infection, we immunoprecipitated MAVS using Ni-NTA 
beads and detected its interaction with RIG-I, CARMA3 and BCL10 by immunoblotting. We 
found that RIG-I interacted with MAVS in the absence of CARMA3 or BCL10. After the 
overexpression of CARAM3 or BCL10, the interaction between MAVS and RIG-I was 
blocked in a dose-dependent manner. In contrast, MAVS was associated with CARMA3 or 
BCL10 even in the presence of RIG-I. Together, our data suggested that CARMA3 and 
BCL10 competed with RIG-I in binding with MAVS (Fig.30). 
 
3.19 CARMA3 interacted with CASPASE-3, CASPASE-8 and CASPASE -9. 
 
There is a CARD domain at the N-terminal of CARAM3. CARD domain originates from 
proteins involved in regulation of CASPASE proteins’ activation and recruitment(Jiang and 
Lin 2012).  CARMA3 was cleaved after virus infection. The cleavage sites might be located 
in the middle of CARMA3. By sequence analyses, we identified a potential CASPASE 8 
cutting site in the middle of protein. Therefore, we hypothesized that CARMA3 interacts 
with CASPASE proteins after virus infection. To test the hypothesis, we infected A431 cells 
with VSV at MOI=3. At the different time points after infection, we immunoprecipitated 
CASPASE3, 8 and 9 using their specific antibodies-conjugated beads. CARMA3 
constitutively interacted with CASPASE 3, 8 and 9. They interacted with each other with the 
highest affinity at 4 hours after virus infection. At 8 hours after infection, we can only detect 
the weak interaction between CARMA3 and CASPASE 3, while CASPASE 8 and 9 were 
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dissociated from CARMA3 (Fig.38).  The interaction between CARMA3 and CASPASE 
proteins raised the possibility that CARMA3 was cleaved by CASPASE proteins. More 
studies are needed to test the hypothesis.  
 
3.20 The aggregation of MAVS was required for NF-κB and IRF3 activation 
 
Previous studies showed that MAVS was aggregated to form a prion-like structure after 
SeV infection. The prion-like structure of MAVS was important for MAVS to recruit many 
different E3 ligases, such as TRAF6, TRAF2/5, linear ubiquitin assembly complex (Lubac) 
complex, which work together to activate NF-κB and IRF3 (Hou, Sun et al. 2011). To 
confirm it, we obtained two plasmids encoding MAVS WT or MAVS E26A and 
overexpressed them with NF-κB-luc and IFN-luc in HEK 293 cells. It was found that MAVS 
WT but not MAVS E26A formed prion-like structure, when they were overexpressed (Hou, 
Sun et al. 2011). MAVS WT induced the activation of both signaling pathways, while the 
mutant cannot. Next, we detected the level of these two proteins by immunoblotting. We 
found that the level of these two proteins were comparable. Our data suggested that the 
aggregation of MAVS was required for both NF-κB and IRF3 activation (Fig.31). 
 
3.21 CARMA3 and BCL10 overexpression inhibited MAVS to form prion-like 
structure. 
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Our previous data showed that CARMA3 and BCL10 interacted with MAVS and 
regulated MAVS function. Additionally, MAVS aggregation was essential for both NF-κB 
and IRF3 activation. Therefore, we hypothesized that CARMA3 or BCL10 overexpression 
inhibits MAVS aggregation. To test the hypothesis, we overexpressed different doses of 
CARMA3-FLAG together with RIG-I-FLAG in HEK 293 cells. Then, we isolated 
mitochondrial from transfected cells and analyzed MAVS aggregation by SDD-AGE assay. 
We found that overexpression of RIG-FLAG led to MAVS aggregation, while the MAVS 
aggregation was inhibited with increasing amount of CAMRA3 in mitochondrial (Fig.32). 
Next, we decided to check the role of BCL10 in regulating MAVS aggregation. We 
overexpressed different doses of BCL10 together with RIG-I-FLAG in HEK 293 cells. Then, 
we decided to detect the MAVS aggregation using the methods as described before. We 
found that BCL10 overexpression inhibited MAVS aggregation in a dose-dependent manner 
(Fig.32). 
Together, our data suggested that CAMRA3 and BCL10 overexpression inhibited MAVS 
from aggregated form. 
 
3.22 After virus infection, MAVS aggregation more easily occurred in cells 
with CARMA3 deficiency. 
 
To further confirm the negative role of CARMA3 in MAVS aggregation, we infected WT 
and CARAM3 deficient MEF cells with VSV at MOI=3. At the different time points, we 
measured the MAVS aggregation using the method as described previously. One hour after 
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virus infection, MAVS did not undergo aggregation in WT cells, but MAVS aggregation 
occurred in CARMA3 deficient cells. This trend became more obvious at 6 hours after virus 
infection. Next, we checked the level of MAVS in WT and CARMA3 deficient MEF cells in 
mitochondrial. We found that the level of MAVS was comparable between two cell types. 
Therefore, our data suggested the negative role of CARMA3 in MAVS aggregation (Fig.33). 
 
3.23 Schematic model of CARMA3 and BCL10-mediating MAVS aggregation 
and MAVS-mediating signaling pathway. 
 
Based on our previous data, we propose a model to describe how CARMA3 and BCL10 
regulate MAVS aggregation in RIG-I/MAVS signaling pathways. In resting cells with no 
virus infection, MAVS was kept as an individual form. After virus infection, RIG-I interacted 
with MAVS and triggered the MAVS to form a prion-like structure. During the process, 
CAMRA3 and BCL10 complex interacted with MAVS and was involved in the activation of 
NF-κB signaling pathway. In the meantime, the CARMA3 and BCL10 complex inhibited 
MAVS from more aggregated form. In CARMA3 deficient cells, virus infection triggered the 
quick and easy MAVS aggregation. Therefore, in CARMA3 deficient cells, there was more 
activation of TBK1-IRF3 signaling pathway. Since CARAM3 and BCL10 are involved in 
NF-κB through unknown mechanism, there was partially defective of virus-induced NF-κB 
activation (Fig.34). 
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3.24 Compared to WT mice, CARMA1-deficient  mice had less serum IFNβ 
and IL6 levels after VSV-GFP infection 
 
CARMA1 is another CARMA family member. Different from CARMA3, the CARMA1 
is only expressed in the hematopoietic tissues. However, CARMA1 shared a high degree of 
sequence and structural homology with CARMA3(Jiang and Lin 2012). Furthermore, 
CARMA3 had an ability to rescue TCR-induced NF-κB activation in CARMA1-deficient T 
cells, which suggested that CARMA3 and CARMA1 regulate the same signaling pathway in 
a similar manner but in different tissues (Matsumoto, Wang et al. 2005). Therefore, we 
hypothesized that CARMA1 contributes to the variable host responses to VSV infection, 
similar to CARMA3. To test it, we challenged WT and CARMA3 deficient mice intranasally 
with VSV-GFP infection. We checked cytokine production in serum and virus titer in brain. 
We found that virus titer in CARMA1 deficient mice exhibits modestly decreased virus titer, 
compared to WT mice. (Fig.35A). However, we surprisingly found that the serum IL6 and 
IFNβ was significantly decreased in CARMA1 deficient mice at 24 and 48 hours after 
infection, but the level of serum IFNε is comparable between two types of mice (Fig.35B). It 
suggested that CARMA1 specifically regulated VSV-induced the production of IL6 and 
IFNβ. 
 
3.25 CARMA1 contributed to VSV-induced the production of IFNβ in 
splenocyte and CD11c+ cells. 
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Our previous data showed that the serum IL6 and IFNβ was decreased in CARMA1 
deficient mice at 24 or 48 hours after VSV infection. It suggested that CARMA1 mainly 
contributed to the innate immunity against VSV infection. Additionally, multiple dendritic 
cell types served as major IFNs producing cells in vivo in response to RNA virus 
infection(Colonna, Krug et al. 2002, Diebold, Montoya et al. 2003). Therefore, we 
hypothesized that CARMA1 contributes to VSV-induced IL6 and type I interferons 
production in dendritic cells in vivo. To do that, we directly sorted CD11c+ from the spleen of 
infected WT and infected CARMA1 mice. Before sorting, one part of cells from spleen was 
kept. Then, we detected the cellular production of IFNβ by RT-PCR. We found that the 
production of INFβ in splenocytes from CAMRA3 deficient mice is nearly 10 folds less than 
WT mice, while the difference goes up to nearly 20 fold in CD11c+ cells(Fig.36). It 
suggested that CARMA1 contributed to VSV-induced the production of IFNβ in splenocyte 
and CD11c+ cells.  
 
 
3.26 CARMA1 deficiency did not affect VSV-induced the production of IL6 
and IFNβ in BMDMs. 
 
Next, we decided to study the role of CARMA1 in VSV-induced the production of IL6 
and IFNβ in macrophage. To test the hypothesis, we cultured primary BMDMs isolated from 
WT or CARMA1 deficient mice as previously described. Then, we infected the primary 
cultures of BMDMs with VSV at MOI=3 and detected the production of IL6 and type I IFNs. 
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We found the production of either IL6 or type I IFNs is comparable in BMDMs from both 
types of mice after infection (Fig.37 A, B&C). Consistently, the activation of TBK1-IRF3 
was also similar in BMDMs from both types of mice (Fig.37D). It suggested that CARMA1 
deficiency did not affect VSV-induced the production of IL6 and IFNβ in macrophage. 
 
3.27 Identification of CARMR3 binding partners by SILAC experiment. 
 
To further characterize the CARMA3 signaling complex, we preformed SILAC 
experiment to identify proteins that interact with CARMA3.Extraction from HEK 293T cells 
expressing vector was labeled with ‘light’ isotopes, while extraction from HEK 293T cells 
expressing CARMA3-FLAG was labelled with ‘heavy’ isotopes. After immunoprecipitation 
with FLAG antibody conjugated beads, the precipitates from the heavy and light samples 
were subject to SDS-PAGE and silver staining. The precipitates were excited from the gel 
and digested with trypsin. The peptides were analyzed by nano liquid chromatography 
tandem mass spectrometry(nanoLC-MS/MS). 512 different proteins were identified by 
analyses of nanoLC-MS/MS (Figure 39B). 25 proteins enriched in the heavy sample were 
considered as CARMA3 binding partners (Table 3). Among them, we found that CARMA3 
has highest mass score, suggesting the success of the whole SILAC experiment (Figure 39C). 
Gene ontology(GO) analysis was performed using Uniprot. We found that GO terms for 
cellular process, metabolic process, biological regulation and single-organism process were 
enriched in CARMA3 binding partners.  We also found that CARMA3 interacts with Zinc 
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finger CCCH-type antiviral protein 1(ZAP), which prevents infection by retroviruses (Gao, 
Guo et al. 2002). 
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Table 1 TLRs and some of their important ligands  
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Table 2 The primers used in the experiments 
 Forward Primers Backward Primers 
Mouse ifnα TGACCTCAACACTCAGCTCAA AGGTGCCTGTATCTCTACCTG 
Mouse ifnβ CAGCTCCAAGAAAGGACGAAC GGCAGTGTAACTCTTCTGCAT 
Mouse il6 TCTATACCACTTCACAAGTCGGA GAATTGCCATTGCACAACTCTTT 
Mouse gapdh AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 
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Table 3 The cellular binding partners of CARMA3. 
 
 
 
 
Accession Score Mass H/L Description
HEBP1_HUMAN 20 21234 1239 Heme-binding protein 1 OS=Homo sapiens GN=HEBP1 PE=1 SV=1
NB5R4_HUMAN 18 59839 263.7 Cytochrome b5 reductase 4 OS=Homo sapiens GN=CYB5R4 PE=1 SV=1
PWP1_HUMAN 131 55793 198.2 Periodic tryptophan protein 1 homolog OS=Homo sapiens GN=PWP1 PE=1 SV=1
ZN638_HUMAN 23 220488 161.3 Zinc finger protein 638 OS=Homo sapiens GN=ZNF638 PE=1 SV=2
DDX23_HUMAN 36 95524 151.8 Probable ATP-dependent RNA helicase DDX23 OS=Homo sapiens GN=DDX23 PE=1 SV=3
EXOS5_HUMAN 57 25233 128.5 Exosome complex component RRP46 OS=Homo sapiens GN=EXOSC5 PE=1 SV=1
CD043_HUMAN 96 23849 96.63 UPF0534 protein C4orf43 OS=Homo sapiens GN=C4orf43 PE=1 SV=2
EEPD1_HUMAN 16 62767 83.57 Endonuclease/exonuclease/phosphatase family domain-containing protein 1 OS=Homo sapiens GN=EEPD1 PE=1 SV=2
COR1B_HUMAN 57 54200 76.61 Coronin-1B OS=Homo sapiens GN=CORO1B PE=1 SV=1
TOP3A_HUMAN 15 113083 75.72 DNA topoisomerase 3-alpha OS=Homo sapiens GN=TOP3A PE=1 SV=1
RTC1_HUMAN 115 39311 57.1 RNA 3'-terminal phosphate cyclase OS=Homo sapiens GN=RTCD1 PE=1 SV=1
PRP4_HUMAN 135 58412 46.47 U4/U6 small nuclear ribonucleoprotein Prp4 OS=Homo sapiens GN=PRPF4 PE=1 SV=2
ZER1_HUMAN 16 88612 44.74 Protein zer-1 homolog OS=Homo sapiens GN=ZER1 PE=1 SV=1
CAR10_HUMAN 8141 115859 35.37 Caspase recruitment domain-containing protein 10 OS=Homo sapiens GN=CARD10 PE=2 SV=2
ZCCHV_HUMAN 125 101367 35.2 Zinc finger CCCH-type antiviral protein 1 OS=Homo sapiens GN=ZC3HAV1 PE=1 SV=3
ASCC2_HUMAN 77 86306 25.51 Activating signal cointegrator 1 complex subunit 2 OS=Homo sapiens GN=ASCC2 PE=1 SV=3
K1C10_HUMAN 96 58792 16.78 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6
RBM42_HUMAN 116 50749 12.38 RNA-binding protein 42 OS=Homo sapiens GN=RBM42 PE=1 SV=1
SNUT1_HUMAN 403 90200 4.788 U4/U6.U5 tri-snRNP-associated protein 1 OS=Homo sapiens GN=SART1 PE=1 SV=1
UBF1_HUMAN 190 89350 4.37 Nucleolar transcription factor 1 OS=Homo sapiens GN=UBTF PE=1 SV=1
P5CS_HUMAN 269 87248 2.726 Delta-1-pyrroline-5-carboxylate synthase OS=Homo sapiens GN=ALDH18A1 PE=1 SV=2
XRN2_HUMAN 588 108513 2.442 5'-3' exoribonuclease 2 OS=Homo sapiens GN=XRN2 PE=1 SV=1
RLA1_HUMAN 697 11507 2.366 60S acidic ribosomal protein P1 OS=Homo sapiens GN=RPLP1 PE=1 SV=1
FUS_HUMAN 236 53394 2.125 RNA-binding protein FUS OS=Homo sapiens GN=FUS PE=1 SV=1
SFPQ_HUMAN 265 76102 2.068 Splicing factor, proline- and glutamine-rich OS=Homo sapiens GN=SFPQ PE=1 SV=2
  
 
Figure 1 TLRs in antivirus response.
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Figure 3 IFNs signaling pathway
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Figure 5 CARMA3 deficiency caused mice to be more resistant to the infection of H1N1 
influenza virus. (A) Groups of 6-8 weeks WT or CAMRA3 deficient mice were intranasally 
infected with H1N1 influenza virus at pfu=600. The change of mice bodyweight had been 
measured daily until 2 weeks after virus infection. (B) WT, CARMA3 Het, CARMA3 
deficient mice were intranasally infected with H1N1 influenza virus at pfu=500. Lungs from 
different mice were harvested at 2 days after virus infection. The virus titer in lungs was 
measured by the TCID50 assay with MDCKII cells. 
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Figure 6 CARMA3 deficient mice had enhanced lung IFNβ production and decreased 
level of serum IL6 after the infection of H1N1 influenza virus. Groups of 6-8 weeks WT 
or CAMRA3 deficient mice were intranasally infected with H1N1 influenza virus at pfu=600.  
(A) The serum was harvested 0, 3, 6 days from WT and CARMA3 KO mice. The serum IL6 
from mice was measured by ELISA. (B) The lungs form mice were harvested 3 days after 
infection. The mRNA was isolated from superior lobe of mice right lung using Trizol reagent. 
The production of IFNβ was measured by qPCR using specific mouse ifnβ primers.  
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Figure7 CARMA3 deficiency 
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Figure 9 The activation of NF
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both cell types was collected at 16 hours after virus infection. The protein amount of IL6 in 
supernatant was measured by ELISA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
  
 
Figure 10 CARMA3-deficient c
pathway and increased production 
CARMA3 Het and CARMA3 
different time points, the supernatant from cell was collected 
ELISA, whereas the cells were harvested for mRNA 
IFNβ was measured by both q
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Figure 11 CARMA3 deficiency 
VSV infection. Primary WT and CARMA3 deficient MEF cells, Hela cells with 
CARMA3 knockdown, A431 cells with control or CARMA3 
VSV at MOI=10. At 1 hour after virus infection, the 
replaced with the fresh medium
supernatant was measured using 
 
 
 
 
 
 
73 
 
contributed to reduction in viral yield in vitro
knockdown were infected with 
supernatant from each cell type 
 to get rid of uninfected virus. The virus amount in 
viral plaque assay at 24 hours after infection.
 after 
control or 
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Figure 12 CARMA3-deficient MEF 
IL6 after poly (I:C) transfection
cells were transfected with 1µ
points after transfection, the supernatant from both cell types was collected 
analyses, whereas the cells were harvested for mRNA 
measured both by qPCR using the specific 
and CARMA3 deficient MEF cells were transfected with 1
2000. At the different time points after transfection, the nuclear proteins were isolated as 
previously described. The NF
κB and OCT-1 probe. 
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.(A) and (B) Primary WT and CARMA3 deficient
g/ml poly(I:C) by lipofectamine 2000. At the different time 
for the 
isolation. The production of IL6
mouse IL6 primers and ELISA.  (C) Primary WT 
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 MEF 
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Figure13 CARMA3-deficient MEF 
pathway and produced more type I IFNs
CARMA3 deficient MEF cells were transfected with 1
At the different time points after transfection, t
collected for the ELISA analyses
nuclear proteins were isolated as previously described. 
was measured both by qPCR
production of IFNα was measured by q
activation of TBK1-IRF3 sig
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, whereas the cells were harvested for mRNA 
 (A) and (C) The production of IFN
 using the specific mouse IFNβ primers and ELISA. (B) The 
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Figure 14 CARMA3-deficient MEF 
ppp-dsRNA. Primary WT and CARMA3 
5’ppp-dsRNA or its control by
transfection, the supernatant from both cell types was collected 
whereas the cells were harvested for mRNA 
measured both by qPCR using the specific IL6 primers and ELISA.
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cells produced less IL6 after the transfection
deficient MEF cells were transfected with 1
 lipofectamine2000. At the different time points after 
for the ELISA 
isolation. (A) and (B) The production of IL6 was 
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analyses, 
  
 
Figure 15 CARMA3-deficient MEF 
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Figure 16 BCL10-deficient MEF 
poly (I:C) transfection.(A) BCL10 Het
VSV at MOI=3.At the different time points after infection, mRNA was isolated from cel
The production of IFNβ was measured by q
Het and BCL10 deficient MEF cells were transfected with 1
lipofectamine2000. At the different time points after infection, mRNA was isolated from 
cells. The production of IFNβ
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PCR using the specific IFNβ primers
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Figure 17 BCL10-deficient MEF 
pathway after VSV infection
with VSV at MOI=3. The activation of TBK1
specific p-TBK1 and p-IRF3 antibodies. 
BCL10 was detected as control to 
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cells had hyperactivation of TBK1-IRF3 signaling 
. BCL10 Het and BCL10 deficient MEF cells were infected 
-IRF3 signaling pathway was measured by 
TBK1 and IRF3 were detected as a loading control.
indicate cell types.  
 
  
 
Figure 18 BCL10-deficient MEF 
poly (I:C) transfection.(A) BCL10 Het and BCL10 
VSV at MOI=3. At the different time points after infection, mRNA was isolated from cells. 
The production of IL6 was measured by q
Het and BCL10 deficient MEF cells were transfected with 1
the different time points after infection, mRNA was isolated from cells. The production of 
IL6 was measured by qPCR using the specific 
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cells produced less IL6 after VSV infection
deficient MEF cells were infected with 
PCR using the specific IL6 primers. (B) BCL10 
µg/ml by lipofectamine
IL6 primers. 
 and the 
e2000. At 
  
 
Figure 19 A549 cells stably 
hyperactivation of TBK1-IRF3 
expressing control shRNA, CARMA3 shRNA or BCL10 
MOI=3. The activation of TBK1
and p-IRF3 antibodies. TBK1 and IRF3 were 
detected as control to indicate 
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expressing CARMA3 shRNA or BCL10 shRNA ha
signaling pathway after VSV infection.A549 cells stably 
shRNA were infected with VSV at 
-IRF3 signaling pathway was measured by specif
detected as a loading control. BCL10 was 
BCL10 knockdown efficiency. 
d 
ic p-TBK1 
  
 
Figure 20 A549 cells stably 
shRNA produced less IL6 and more IFN
expressing GFP shRNA, CARMA3 shRNA or BCL10 
MOI=3. At the different time points after infection, mRNA was isolated from cells. The 
production of IL6 and IFNβ was measured by qPCR
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expressing GFP shRNA,CARMA3 shRNA or BCL10 
β after VSV infection.A549 cells stably 
shRNA were infected with VSV at 
 using the specific IL6 and IFNβ primers 
  
 
 
Figure 21 BCL10 deficiency 
Groups of 6-8 weeks WT or BCL10 deficient mice were 
at pfu=1×107.  Spleens and brain
virus titer in different tissues was measured by
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s were harvested from mice at 2 days after infection. The 
 viral plaque assay. 
 infection. 
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Figure 22 MALT1 deficiency did not impair VSV
(B) and (C) Primary WT and 
MOI=3.At the different time points after infection, mRNA was isolated from cells. The 
production of IL6 and type I IFNs were
IFNβ primers.(D) Primary WT
MOI=3.At the different time points after infection, 
production of IFNβ were measured
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-induced type I IFNs production.
MALT1 deficient MEF cells were infected with VSV at 
 measured by qPCR using the specific 
 and MALT1 deficient MEF cells were infected with VSV at 
supernatant was isolated from cells. The 
 by ELISA. 
(A), 
IL6, IFNα and 
  
 
Figure 23 MALT1 deficiency did not affect 
WT and MALT1 deficient MEF cells were infected with VSV at MOI=3
time points after infection, the nuclear and the cytoplasmic proteins were isolated as 
previously described. The NF
κB and OCT-1 probe. The cytoplasmic proteins were 
indicated antibodies. 
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VSV-induced NF-κB activation
.At 
-κB activation was measured by EMSA using 32
subject to immunoblotting using the 
. Primary 
the different 
P-labeled NF-
  
 
Figure 24 MALT1 deficiency did not 
and MALT1 deficient MEF cells were infected with VSV at MOI=3
points after infection, the total cell lysates
using indicated antibodies.  
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affect VSV-induced IRF3 activation
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Figure 25 The inhibition of NF
phosphorylation of IRF3. Primary MEF cells were pretreated with NF
an hour, which can block the translocation of p50. Then, primary MEF cells were infected 
with VSV at MOI=3 for indicated time. 
protein extraction. Another part of cells 
activation was measured by specific p
detected as a loading control. The NF
 
 
87 
 
-κB signaling pathway did not enhance the 
-κB inhibitor
Then, one part of cells was harvested for nuclear 
was harvested for immunoblotting.  The IRF3 
-IRF3 antibody. IRF3, TBK1 and ACTIN were 
-κB activation was measured by EMSA.
 for half 
 
  
 
Figure 26 The inhibition of 
of IRF3. Primary WT and CARMA3 deficient 
cycloheximide (CHX) to block new protein synthesis. Then cells were 
ug/ml poly (I:C) by lipofectamin
was measured by immunoblotting
detected as a loading control.
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new protein synthesis did not enhance the phosphorylation 
MEF cells were pretreated with 10 ug/ml
transfected with 1 
e2000. At the different time points, the activation
 using specific p-IRF3 antibody. IRF3 and ACTIN were 
 
 
 of IRF3 
  
 
Figure 27 CARMA3 and BCL10 work
TBK1 or IKKε. (A) HEK 293
BCL10 shRNA were transfected with 
IFNβ-luc. At 24 hours after transfection, 
luciferase assay. (B) HEK 293
BCL10 shRNA were transfected with 
IFNβ-luc. At 24 hours after transfection,
by luciferase assay. (C) HEK 293
BCL10 shRNA were transfected with 
IFNβ-luc. At 24 hours after transfection, the NF
luciferase assay. (D) After transfection
subjected with immunoblotting
89 
ed downstream of MAVS, but upstream of 
 cells stably expressing control shRNA, CARMA3 shRNA, 
the plasmids encoding MAVS-Flag with NF
both NF-κB and IRF3 activation were measured by 
 cells stably expressing control shRNA, CARMA3 shRNA or 
the plasmids encoding TBK1-Flag with 
 both the NF-κB and IRF3 activation were measured 
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plasmids encoding IKKε-Flag with NF
-κB and IRF3 activation were measured by 
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 using indicated antibodies. 
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Figure 28 CARMA3 and BCL10 
in HEK 293 cells. We overexpressed 
MYC (B) with MAVS-FLAG or RIG
transfection, MAVS or RIG-I was 
The immunoprecipitated complex and cell lysates were subjected with
analysis with anti-FLAG antibody (
anti-MYC (BCL10) and other 
 
 
  
 
 
 
90 
 
interacted with MAVS, when they are overexpressed 
the plasmids encoding CARMA3-HA 
-I-FLAG in HEK 293 cells. At 24 hours after 
immunoprecipitated using anti-Flag-conjugated
 immunoblotting 
MAVS or RIG-I), anti-HA antibody (CARMA3)
indicated antibodies. 
(A) or BCL10-
 beads. 
 and 
  
 
Figure 29 CARMA3 and BCL10 
deficient MEF cells were infected with 
Then, we infected cells stably expressing CARMA3
time points, cell lysates were 
conjugated beads. The immunoprecipated complex and cell lysates we
immunobloting analysis with
anti-TUBULIN antibodies. (B) 
lipofectamine2000. At different time points, cell lysates were 
BCL10-conjugated or control anti
and cell lysates were subjected with
anti-TRAF6 antibodies. 
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interacted with MAVS. (A)The immortalized 
lentivirus constructions encoding CARMA3
-HA with VSV at MOI=3. At different 
immunoprecipitated using anti-HA- or control anti
re subjected with
 anti-HA (CARMA3), anti-MAVS, anti-CARMA3, anti
HEK 293 cells were transfected with 1 ug/ml 
immunoprecipitated using anti
- IgG-conjugated beads. The immunoprecipated complex 
 immunoblotting analysis with anti-BCL10, anti
CARMA3 
-HA. 
-IgG-
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poly (I:C) with 
-
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Figure 30 CARMA3 and BCL10
His and RIG-I-FLAG were overexpressed 
BCL10-MYC in HEK 293 cells.
using Ni-NTA magnetic beads
with immunoblotting analysis with
(BCL10), anti-HA (CARMA3)
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 competed with RIG-I in binding with MAVS
in presence of different doses of CARMA3
 At 24 hours after infection, cell lysates were precipitated 
. The precipitated complex and cell lysates were subjected 
 anti-HIS (MAVS), anti-FLAG (RIG-I), anti
 antibodies. 
.MAVS-
-HA or 
-MYC 
  
 
Figure 31 The aggregation of MAVS 
HEK 293 cells were transfected
E26A-FLAG in presence of plasmids encoding NF
IRF3 activation were measured by luciferase assay. C
subjected with immunoblotting 
anti-ACTIN antibodies. 
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was required for NF-κB and IRF3 
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ell lysates from transfected cells
analysis with anti-FLAG (MAVS WT and MAVS E26A
activation. 
 or MAVS 
-κB and 
 were 
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Figure 32 The interaction between CARMA3 or BCL10 with MVAS inhibited MAVS 
to form prion-like structure. HEK 293 cells were transfected with plasmids overexpressing 
RIG-I-FLAG and different dose of BCL10-MYC (A) or CARMA3-FLAG (B).  24 Hours 
after transfection, mitochondrial and cell lysates were isolated from transfected cells. Then 
mitochondrial were lysed and subjected with SDD-AGE to detect MAVS aggregates. Cell 
lysates were subjected with immunoblotting with the indicated antibodies. 
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Figure 33 CARMA3 deficiency in cells led to increased aggregation of MAVS after 
virus infection. Primary WT and CARMA3 deficient MEF cells were infected with VSV at 
MOI=3. At the different time points after infection, mitochondrial and cell lysates were 
isolated from cells. Then, mitochondrial were lysed and subjected with SDD-AGE to detect 
MAVS aggregates. Cell lysates were subject to immunoblotting with the indicated antibodies. 
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Figure 34 Schematic models of CARMA3 and BCL10-mediating MAVS aggregation and 
MAVS-mediating signaling pathway 
 
 
 
 
 
 
 
 
  
  
 
 
Figure 35 Compared to WT mice, CARMA1
IL6 after VSV infection. Groups of 6
intranasally infected with VSV at pfu=1
infected mice at 24 or 48 hours after VSV
in brains were taken by fluorescence microscope
measured by ELISA. 
B 
A 
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-deficient mice had less serum 
-8 weeks WT or CAMRA1 deficient mice were 
×107. Serum or brains were harvested from the 
-GFP infection. (A) The pictures of the VSV
. (B) Serum IL6, IFNβ and IFN
IFNβ and 
-GFP 
γ were 
  
 
Figure 36 CARMA1 contributed to VSV
and CD11c+ cells.6-8 weeks WT or CAMRA1 deficient mice were 
VSV at pfu=1×107. Serum, splenocyte and 
from the infected mice at 24 hours 
were measured by the corresponding ELISA kits. (B) The production of IFN
types of cells was measured by RT
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-induced the production of IFNβ
intranasal
CD11c+ cells from splenocyte were harvested 
after VSV-GFP infection. (A) The serum IFN
-PCR. 
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ly infected with 
β and IL6 
β from different 
  
 
Figure 37 CARMA1 deficiency did
IFNβ in BMDMs. BMDM was harvested from 
deficient BMDMs were infected with VSV at pfu=3. (A) The production of type I IFNs 
measured by RT-PCR. (B) The production of IL6 was measured by RT
from infected cells were subject to
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 not affect VSV-induced the production of IL6 and 
different types of mice. WT and CARMA1 
-PCR. (C) Cell lysates 
 immunoblotting using indicated antibodies.
was 
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Figure 38 CARMA3 interacted with CASPASE-3, CASPASE-8 and capase-9.A431 cells 
were infected with VSV at pfu=3. At different time points, cell lysates were subjected with 
immunoblotting using indicated antibodies or immunoprecipitated using anti-CARMA3, 
CASPASE8, CASPASE9 or CASPASE3 antibodies-conjugated beads. The 
immunoprecipitated complexes were subjected with immunoblotting using indicated 
antibodies. 
 
 
 
 
 
 
  
 
Figure 39 SILAC experiments to identify CARMA3’s 
Workflow chart of the SILAC experiment. (B) Numbers of differential proteins and total 
proteins identified. The pie chart show
proteins identified. (C) A representative spectru
ontology(GO) analysis was performed using Uniprot.
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CHAPTER 4: DISCUSSION 
 
Using WT MEF cells and CARAM3 or BCL10 deficient cells, we showed that CARMA3 
and BCL10 played a positive role in RIG-I/MAVS-mediated NF-κB activation, whereas a 
negative role in RIG-I/MAVS-mediated IRF3 activation. As a result, CARMA3 or BCL10-
deficient cells produced less IL6, but more type I IFNs than WT cells did, upon VSV 
infection or specific ligands transfection.  It was found that type I IFNs produced by cells 
constituted the host first defense line against virus infection(Schneider, Chevillotte et al. 
2014). Therefore, we found that CARMA3 deficient cells had less VSV replication after 
infection. VSV and influenza mice model also confirmed the negative role of CARMA3 and 
BCL10 during virus infection. Both in VSV and influenza mice model, CARMA3 deficient 
mice had less virus titer than WT mice did.  Furthermore, CARMA3 deficient mice had more 
local IFNβ production after virus infection. Mechanistic study showed that CARMA3 and 
BCL10 interacted with MAVS and directly regulated MAVS activities. CARMA3 and 
BCL10 overexpression inhibited MAVS aggregation triggered by RIG-I overexpression. 
Furthermore, MAVS more easily underwent aggregation in CARMA3 deficient cells, 
compared to the WT cells. Together, these findings provided a strong evidence to show the 
important role of the CARMA3 and BCL10 in orchestrating NF-κB and IRF3 activation. 
Seasonal influenza virus outbreak in human results in about 3~5 million cases of severe 
illness and around 500,000 deaths worldwide (Lozano, Naghavi et al. 2012). H1N1, 
H2N2and H3N2 are the best-known IAVs currently circulating in humans. Additionally, 
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avian influenza strains, such as H5N1 and H7N9, are emerging highly pathogenic strains 
with significant pandemic potential and post a serious threat to global public health (Yen and 
Webster 2009, Lam, Wang et al. 2013). Therefore, it is critical to study the host immune 
response against IAV, which may facilitate the rational design of interference therapeutic.  
It has been found that genetic diversity contributes to broad host responses and outcomes 
upon IAV infection. Revealing genetic variations will provide the important information for 
our understanding of antiviral immune responses. It is well known that genetic variations 
between different mouse strains contribute to diverse phenotypic responses to IAV infection.  
Therefore, it is reasonable to use mouse models to reveal genetic diversity for host 
susceptibility to IAV infections and thereby, to identify many important genes associated 
with host responses, for example, the landmark discovery of TLR4(Poltorak, He et al. 1998). 
Recently, Ferris et al has been identified three novel quantitative trait loci (QTL) that may 
contribute to the mice susceptibility for IAV infection, using incipient lines of mice with 
highly genetical diversity. CARD10 that encodes CARMA3 was found within one of QTL. 
However, the role of CARMA3 during IAV infection remains largely unknown.  Previous 
studies from our lab and others indicate the important role of CARMA3 in NF-κB signaling 
pathway (Grabiner, Blonska et al. 2007, McAllister-Lucas, Ruland et al. 2007, Jiang, 
Grabiner et al. 2011). However, the role CARMA3 in response to virus infection has not 
been investigated before. In the study, we studied the role of CARMA3 and BCL10 in RIG-
I/MAVS signaling pathway for the first time, which suggests that CARMA3/Card10 may be 
the genes contributing to the observed phenotype found in the study by Ferris et al (Ferris, 
Aylor et al. 2013). It was found that influenza NS1 protein interacted with some PDZ-
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containing proteins and inhibited the cellular anti-virus response, for example, the production 
of IFNβ(Medina and Garcia-Sastre 2011). CARMA3 contains a PDZ domain and plays an 
important role in anti-virus response. It would be interest to study whether CARAM3 is one 
of host protein targeted by virus protein. Establishing these new paradigm will provide the 
molecular basis for our future research to investigate whether the differential mutations or 
SNP of CARMA3 (and its associated complex) contributes to the distinct response in human 
patients to IAV (or other respiratory viruses) infection. 
Our data suggested that CARMA3 and BCL10 played a positive role in RIG-I/MAVS-
mediated NF-κB activation, but a negative role in RIG-I/MAVS-mediated IRF3 activation. 
Therefore, CARMA3 or BCL10 served as a “switch” to orchestrate NF-κB and IRF3 
activation in RIG-I/MAVS signaling pathway, which was different from other regulators.  
Most of them only had a unique role in both pathways.  For example, the nucleotide-binding 
domain and leucine-rich repeat containing family member 1(NLRX1) inhibited the 
interaction between MAVS and RIG-I and thereby, inhibiting both NF-κB and IRF3 
activation (Allen, Moore et al. 2011). Similarly, focal adhesion kinase(FAK) interacted with 
MAVS on the outer membrane of mitochondrial in a virus-dependent manner and inhibited 
the MAVS signaling(Bozym, Delorme-Axford et al. 2012). Another example is laboratory of 
genetics and physiology 2 (LGP2), which serves a negative role in RLR pathway by 
interfering the interaction between MAVS and downstream many E3 ligases (Komuro and 
Horvath 2006, Tang and Wang 2009).  
Similar to CARAM3 and BCL10, the linear ubiquitin assembly complex (LUBAC) also 
plays a dual role in MAVS signaling. LUBAC consists of the E3 ligases HOIL-1L, HOIP and 
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the accessory protein SHARPIN, which functions to stabilize the whole complex. After virus 
infection, SHARPIN-deficient cells (cpdm) produced more type I IFNs, but decreased NF-κB 
activation and less VSV replication. LUBAC induced linear ubiquitination of NEMO, which 
led to NEMO’s association with TRAF3 and thereby, disrupted MAVS-TRAF3 interaction. 
In this way, LUBAC served as a “switch” in both NF-κB and IRF3 signaling pathways by 
regulating the linear ubiquitination of NEMO. The similarity in cellular response during virus 
infection suggested that CARMA3 and LUBAC might share the similar mechanism to 
regulate MAVS signaling. Interestingly, previous studies in our lab showed the CARMA3 
physically interacted with NEMO and regulated IKK activities through NEMO-associating 
ubiquitination. Additionally, linear ubiquitination of NEMO has been shown to play an 
important role in activation of IKK complex in response to different stimulus (Belgnaoui, Paz 
et al. 2012). It may explain why the NF-κB signaling pathway is partially defective in 
CARMA3 deficient cells. More studied are needed to test the hypothesis. All studies 
suggested the complicated regulating mechanisms in RIG-I/MAVS signaling pathways. 
NF-κB signaling pathway can be activated by many viruses throughout different 
mechanisms(Santoro, Rossi et al. 2003). However, it remains controversial that NF-κB 
activity is beneficial to host. On one hand, NF-κB target genes play important roles in the 
activation of the host immune and inflammatory response(Pahl 1999). For example, the NF-
κB activation induced the expression of many genes including many enzymes such as 
cyclooxygenase 2, the inducible form of nitric oxide synthase, a variety of cytokines and 
chemokines, receptors responsible for immune recognition, receptors involved in neutrophil 
adhesion an transmigration across blood vessel walls, proteins required for antigen 
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presentation and etc(Pahl 1999). Additionally, NF-κB activation does not required new 
protein synthesis. Therefore, NF-κB activation is a rapid event that occurs within minutes 
after virus infection, which constitutes the first host defense line against virus 
infection(Hoesel and Schmid 2013). Consistent with this, mice with the deficiency of NF-κB 
family members exhibit susceptible to virus infection. On the other hand, many viruses 
evolve different strategies to hijack NF-κB, including HIV-1, HTLV-1, influenza virus, 
hepatitis B and C virus, Herpes virus and etc(Santoro, Rossi et al. 2003). For example, 
functionally important NF-κB-binding sites have been identified in the genome of several 
viruses, including HIV-1, SV40 and different members of herpesvirus. These viruses utilize 
NF-κB to drive the expression of many viral proteins (Sassone-Corsi, Wildeman et al. 1985, 
Nabel and Baltimore 1987, Cherrington and Mocarski 1989, Rong, Libermann et al. 1992). 
Additionally, the NF-κB is a transcription factor regulating the expression of many anti-
apoptotic genes such as members of the Bcl2 family, cellular inhibitors of apoptosis -1, 2, 
TRAF proteins, and the FLICE-inhibitory protein(Hoesel and Schmid 2013). Therefore, NF-
κB activation improves cellular survival after virus infection, which is prerequisite for 
completion of entire virus life cycle. Moreover, sometimes, aberrant NF-κB activation 
sometimes caused chronic inflammation and leads to tissue damage, which is harmful to the 
host. Therefore, virus-induced NF-κB activation is double-edged sword for both host and 
pathogen survival. 
During RNA virus infection, NF-κB was activated through both TLR-dependent and 
MAVS/RIG-I signaling pathways. It was well established that CARMA3 is not required for 
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TLR-induced NF-κB activation (Jiang, Grabiner et al. 2011, Pan and Lin 2013). In this study, 
we found loss of CARMA3 impaired poly (I:C) and 5’ppp-dsRNA transfection induced NF-
κB activation. This suggests that CARMA3 and BCL10 play a specific role in by RIG-
I/MAVS signaling but not TLR-dependent NF-κB activation. However, in mice model, both 
TLR and RIG-I-dependent signaling pathways contributed to NF-κB activation in immune 
cells. This may explain why we don’t observe significant effect of CARMA3 deficiency in 
systematic IL-6 mRNA at 24 hours post infection of VSV infection.  
CARMA3 deficient cells enhanced the production of IFNβ but decreased NF-κB 
activation after virus infection. It suggested that NF-κB did not play an essential role in IFNβ 
production. Earlier studies revealed that NF-κB could bind to positive regulatory domains II 
( PRDII) in IFN promoter and is required for the assemble of IFNβ enhanceosome.  Single 
base substitutions in κB sites in IFN promoter impaired inducibility of the IFN beta. 
However, there is no endogenous evidence to show the essential role of NF-κB in the IFNs 
induction at that time (Thanos and Maniatis 1995, Merika, Williams et al. 1998, Agalioti, 
Lomvardas et al. 2000). Later, using p65-/- , p50 -/-p65-/- MFE cells, the researchers showed 
that the production of type I IFNs was modest decreased after virus infection(Wang, Hussain 
et al. 2007). Consistently, using p65-/- MFE cells, another two groups confirmed the 
essential role of NF-κB in the early, but not late IFNs induction. It was found p65 deficient 
cells produced less type I IFNs after virus infection at the early time points, but not later time 
points (Basagoudanavar, Thapa et al. 2011). One reasonable explanation is the activation of 
IRF3 or IRF7. The essential role of IRF3 and IRF7 has been demonstrated using mouse 
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model. More importantly, high activation of IRF3 only sufficiently induced the type I IFNs in 
p65-/- MEF cells (Wang, Basagoudanavar et al. 2010, Basagoudanavar, Thapa et al. 2011). 
In our studies, the NF-κB activation was decreased in CARMA3 deficient MEF cell, whereas 
IRF3 activation was enhanced, which resulted in the increased production of type I IFNs. 
CARMA3 and BCL10 may provide a better drug target, considering their dual role in 
MAVS signaling. On one hands, drugs targeting CARMA3 and BCL10 manipulate the 
production of type I IFNs, which inhibit virus proliferation by targeting proteins or functions 
involved in virus life cycle. On the other hands, it suppresses the inflammation by inhibiting 
NF-κB activation, which is double-edged sword during virus infection. Therefore, the 
balance between NF-κB activation and antiviral response is key events for host to survive.  
Drugs targeting CARMA3 and BCL10 may meet the scenario. 
Currently, the prevail view is that the “activated” MAVS undergoes self-aggregation to 
form prion-like structure, which severs as a platform on mitochondrial to recruit many E3 
ligases, including TRAF6, TRAF2, TRAF5 and LUBAC. These E3 ligases play essential 
roles in activating both NF-κB and IRF3. Therefore, the MAVS polymerization is essential 
for both pathways (Hou, Sun et al. 2011). There is something in common between our model 
and prevailing model.  We also confirmed the importance of MAVS self-aggregation in both 
pathways by luciferase assay using plasmids encoding WT MAVA and MVAS E26A. The 
difference between two models lies in different state of MAVS aggregates. Our model shows 
that MAVS self-aggregation was a dynamic process.  Less aggregated MAVS interacts with 
CAMRA3 and BCL10, which is important for NF-κB activation and blocks the formation of 
more aggregated MAVS. After CARMA3 is cleaved, the MAVS undergoes further 
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aggregation to activate both the IRF3 and NF-κB. Compared to previous model, our model 
can explain that NF-κB activates prior to IRF3 activation. Also, 1M GA can block the IRF3 
activation, but cannot block the degradation of IKBα. Furthermore, the data from Liu’s paper 
also supported our model. Using agarose gradient assay, the researchers found the activated 
MAVS exited in complex with different molecular weight. It suggested that MAVS had 
different aggregated status (Hou, Sun et al. 2011).  Additionally, there is IKKβ only in the 
complex with low molecular weight. 
CARMA family has three members, CARMA1, CARMA2, CARMA3, which share 
similar domains structure but with different tissue distribution(Jiang and Lin 2012). It 
suggests that CARMA1 and CARMA3 may regulate the same signaling pathway in a similar 
manner but in different tissues (Grabiner, Blonska et al. 2007). Consistent with this, previous 
studies showed that CARMA1 was the counterpart of CARMA3 in hematopoietic cells 
(Matsumoto, Wang et al. 2005). However, we surprisingly found that CARMA1 played a 
positive role in VSV-induced the production of both IL6 and IFNβ in vivo, which is different 
form CARMA3. CARMA1 deficient mice had less serum IL6 and IFNβ than WT mice did at 
24 hours after virus infection. In contrast, the level of serum IFNγ is similar between WT and 
CARAM1 mice. While in CARMA3 deficient mice, the level of serum IL6 and IFNβ is 
comparable with WT mice. It is well known that IFNs with their receptors are important for 
host immune system against virus infection(Schneider, Chevillotte et al. 2014).Therefore, 
CARMA1 contributed to the innate immunity against virus infection by regulating the 
production of IFNβ.  
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Previous studies mainly focused on revealing the role of CARMA1 in NF-κB 
activation in T cell or B cells and thereby, in adaptive immunity. Therefore, it would be 
interesting to study the role of CARMA1 in innate immunity. Dendritic cells would be a 
candidate cell type used in our future studies, since they are the main IFN producing cells in 
vivo after RNA virus infection(Colonna, Krug et al. 2002). Additionally, using the CD11c+ 
cells from spleen from WT and CARAM1 deficient mice, we found that VSV-induced IL6 
and IFNβ production is decreased in CARMA1 deficient cells. It suggested that CARMA1 
contributed to the production of these two cytokines in dendritic cells. More studies are 
needed to study how CARMA1 contributed to observed phenotype. We will investigate the 
role of CARMA1 in RIG-I-and TLR-dependent signaling pathway in dendritic cells, 
respectively, since RIG-I and TLR system exert antiviral response in a cell type dependent 
manner. For example, RIG-I is required for the production of type I IFNs in conventional 
dendritic cells (DCs). In contrast, plasmacytoid DCs utilized the TLR system rather than 
RIG-I for viral detection (Kato, Sato et al. 2005). It may explain that CARMA1 plays a 
positive role in VSV-induced the production of cytokines, which is different from CARMA3. 
Using bone marrow derived-macrophages, we found that CARMA1 deficiency did 
not affect VSV-induced the production of IL6 and IFNβ in macrophage, since the production 
of two cytokines is similar in cells from WT or CARMA1-deficient mice. Consistent with 
this, the activation of TBK1-IRF3 was also similar in BMDMs from both types of mice. One 
possible explanation for this observation is that other CARD domain containing proteins may 
substitute the CARMA1’s role in macrophage. CARD9 may be the best candidacy. CARD9 
is structurally similar to CARMA family members with N-terminal CARD and a CC domain. 
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However, it lacks the C-terminal MAGUK domain, which is important for plasma membrane 
localization(Blonska and Lin 2011). Without MAGUK domain, CARD9 may reside in 
cytosol and be recruited to signaling complex after activation. Different from CARMA 
family proteins, the CARD9 expression seems to be restricted to myeloid cells such as 
macrophages, dendritic cells and neutrophils(Bertin, Guo et al. 2000, Gross, Gewies et al. 
2006). More recent studies have revealed the important role of CARD9 in RIG-I/MAVS 
signaling pathway (Poeck, Bscheider et al. 2010). The authors found that CARD9-deficient 
myeloid cells produced less IL6 and pro-IL-1β after transfection of RIG-I ligands or dsRNA 
virus infection. Since the transcription of il6 and pro-IL-1β are controlled by NF-κB 
signaling pathway, CARD9 may contribute to RIG-I-mediated NF-κB activation in 
macrophage, which may substitute CARMA1’s role in the same signaling pathway (Poeck, 
Bscheider et al. 2010). 
Although serum IFNβ level is decreased in CARMA1 mice after VSV infection, the 
virus burden in brains of CARMA1 deficient mice is similar to that of WT mice (Fig.35 
A&B).  In contrast, the virus burden in brains of CARMA3 deficient mice is less than that of 
WT mice, while serum IFNβ level is comparable with mice (Fig8 A&B).These dates suggest 
that serum IFNβ level does not correlate with VSV spread in brains. It may due to the fact 
that the peripheral type I IFN would not easily go through blood brain barrier (BBB) to reach 
brain (Detje, Lienenklaus et al. 2014).  Besides, VSV spread in brain is efficiently arrested by 
the local type I interferon (Detje, Meyer et al. 2009). Consistently, using qPCR, we can 
detect more production of IFNβ in brain from CARAM3 deficient mice than that from WT 
mice (Fig8 B), which decreased VSV spread in brain. 
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There are limitations in the present study. Firstly, our experiments relied too much on 
primary MEF cells to study antivirus response, although MAVS and RIG-I had wide tissue 
distribution and shared a similar signaling pathway to activate NF-κB and IRF3 in many 
types except plasmacytoid dendritic cells (Sun, Sun et al. 2006). It is well known that cellular 
antiviral response is determined by both the cell type and virus type. For example, VSV is 
capable of infecting many different types of cells, whereas the main targets of influenza virus 
are epithelial cells. More importantly, the majority of data generated using VSV may not be 
extended to IAV. In this case, we will isolate and differentiate primary lung and airway 
epithelial cells (LECs) from WT and CARMA3 deficient mice, and then infect cells with 
IAV or VSV to measure NF-κB by and TBK1/IRF3 activation as well as the production of 
IFNβ and IL6. Also, we are going to detect virus replication in WT and CARMA3 KO cells 
and the sensitivity of two cell types to virus infection.  
 
Our study suggests a dual role of the CARMA3-BCL10 complex in RIG-I/MAVS-
mediated NF-κB and IRF3 activation and elucidates the mechanism of how CAMRA3 and 
BCL10 regulate MAVS signaling, which may facilitate the development of the 
corresponding methods to manipulate the antivirus response and the production of 
inflammatory cytokines. 
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CHAPTER 5: FUTURE DIRECTION AND PERSPECTIVE SECTION 
 
As a scaffold protein, CARMA3 contains multiple domains for protein-protein 
interaction including CARD domain and PDZ-domain. Here we found that CARMA3 
interacted with MAVS and negatively regulated the formation of MAVS aggregates and 
IRF3 activation. It would be interesting to know which domains and/or residues are required 
for the interaction between CARMA3 and MAVS and thereby, are important for mediating 
RIG-I/MAVS signaling. Fine mapping of CARMA3 will provide insights for further studies 
and drug development. Since there is no cure and effective vaccine available for many RNA 
viruses, it will be important to develop medicine that help reduce inflammation while 
enhance anti-viral response. CARMA3 is such a good target that meets both criteria.   
Furthermore, it was interesting to find that CARMA3 protein level was gradually 
turned over or CARMA3 was cleaved during VSV infection, which may serve as a feedback 
to enhance the IRF3 activation, and meanwhile, to shut down NF-κB activation. The 
presence of CARMA3 during early time of infection inhibited the function of MAVS in 
mediating IRF3 activation. With CARMA3 gradual turnover or cleavage, this inhibitory 
effect weakens and IRF3 activation is activated. Therefore, in the absence of CARMA3 from 
the beginning of virus infection, IRF3 can be activated at greater level and maybe at earlier 
time points as well. Further studies are necessary to address what causes this CARMA3 
turnover or cleaved and how? CASPASE 8 might be a potential protein cleaving CARMA3, 
since we found that CASPASE8 interacted with CARMA3. Additionally, we identified one 
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cleaved band using antibody targeting C-terminal of protein. Using antibody targeting both 
ends of the protein, we identified two cleaved bands. It suggested the cleaved site was 
located in the middle of proteins. Then, based on sequence analyses, we found there was one 
potential CASPASE8 cutting site in the middle of CARMA3. More studies are needed to 
study the role of CASPASE 8 in the cleavage of CARMA3, since it may reveal the role of 
CASPASE 8 in RIG-I/MAVS signaling pathways. 
By SILAC experiment, we identified 25 potential CARMA3 binding partners. Among 
them, ZAP aroused our great interests. ZAP was initially discovered by screening genes that 
prevent retrovirus infection in a cDNA library. Later, the functional studies of ZAP protein 
revealed that the expression of ZAP inhibited the expression of viral genes in the cytoplasm 
without affecting the level of nuclear mRNAs (Gao, Guo et al. 2002). The following studies 
showed that ZAP directly interacted with viral mRNA at ZAP-responsive elements through 
its four CCCH zinc-finger motifs(Jeong, Kim et al. 2010). Then, it recruited polyA-specific 
ribonuclease PARN, 3’-5’ exoribonuclease complex, DCP1-DCP2 decapping complex to 
degrade the RNA body from both 5’ and 3’-ends(Zhu, Chen et al. 2011). ZAP targeting 
viruses includes HIV-1, moloney and murine leukemia virus, xenotropic MuLV-related virus, 
ebola virus, marburg virus, sindbis virus and Ross river virus.  Among them, HIV-1 and 
Ebola also were RIG-I target viruses (Spiropoulou, Ranjan et al. 2009, Wang, Wang et al. 
2013). As a CARAM3 binding partner, ZAP might work together with CARAM3 in the RIG-
I/MAVS signaling pathway. More studies are needed to test this hypothesis.  
By GO analysis, we found that most of CARMA3 binding partners were involved in 
metabolic process (Figure 39D). Additionally, both CARMA3 and BCL10 reside in the 
  
115 
 
mitochondrial (Figure 32&33).  The mitochondrial have been shown to play an important 
role in metabolic pathways including carbohydrate metabolism, fatty acid oxidation, urea 
cycle (Demine, Reddy et al. 2014) . Therefore, in future studies, we are going to investigate 
the role of CAMRA3 in these metabolic pathways. 
In this study, we found that CARMA3 deficient mice showed reduced disease 
symptoms and/or better survival, when challenged with VSV or influenza. These viruses 
represent negative, single-stranded RNA viruses. It will be interesting to see if CARMA3 
indeed play a general effect in response to other RNA viruses. And can this expend to DNA 
viruses?  
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